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ABSTRACT
Monoclonal antibodies have emerged as an important class of cancer therapeutics due to
their ability to specifically bind tumor-expressed antigens. Unfortunately, attempts to treat solid
tumors with these drugs are often limited by an inability of the antibodies to fully penetrate the
tumor tissue, leaving large regions of untargeted and viable cells. The goal of this thesis is to
understand the transport phenomena that contribute to poor antibody distribution in tumors, and
engineer novel antibody variants with improved targeting properties. Previous studies identified
a core set of parameters that impact tumor uptake including antibody size, binding affinity,
plasma clearance rate, and cellular catabolism. Here we probe each of these parameters and its
effect on tumor penetration using a combination of computational modeling and protein
engineering.
In the first part of this thesis, we characterize the cellular internalization kinetics of a
series of anti-carcinoembryonic antigen (CEA) antibodies and antibody fragments. We
demonstrate that internalization is independent of antibody affinity, stability, and valency, and
that the measured rates can be used to mathematically predict antibody penetration distance in
tumor spheroids. Next, we examine the effect of antibody size and affinity by developing a
computational model of in vivo tumor targeting that incorporates size-dependent trends for
capillary permeability, interstitial diffusion, available volume fraction, and plasma clearance.
The model predicts that intermediate size antibody fragments (MW ~30 kDa) have the lowest
tumor uptake with greater accumulation of small and large proteins. To probe size effects
experimentally, we engineered a novel 79 kDa ds(Fv)-Fc antibody fragment that is
approximately half the size of an IgG but retains its binding and Fc salvage activity. In mice, the
ds(Fv)-Fc fragments are cleared from the plasma more rapidly than IgGs but have similar tumor
uptake levels at 24 hours, likely due to higher capillary permeability. In the last section, we
develop a series of matrix metalloproteinase (MMP) activatable antibody fragments that bind
their target antigen up to 300 times faster following cleavage by the tumor expressed protease
MMP-2. We believe that MMP dependent binding should prevent targeting of antigen depots in
healthy tissues and further improve tumor specificity.
Thesis Supervisor: Dane Wittrup
Title: C.P. Dubbs Professor of Chemical Engineering & Biological Engineering
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Chapter 1 - Potential and limitations of antibodies as cancer therapeutics
1.1 - Antibodies as cancer therapeutics
Despite significant improvements in our understanding and treatment of the disease,
cancer remains a leading cause of mortality around the world. In 2008 alone, there were 12.4
million cases causing over 7 million deaths (1). Much of the difficulty in treating cancer stems
from the fact that the standard, first-line treatments of surgical resection, external beam radiation,
and chemotherapy all have significant limitations. Surgery and radiation are often effective at
destroying or removing the primary tumor; however, they are typically unable to eliminate
metastatic disease that has disseminated throughout the body. In contrast, systemically
administered chemotherapeutic agents can target both primary tumors and micrometastases.
Unfortunately, most chemotherapeutic agents act fairly non-specifically by inhibiting cell
division, thereby causing toxicities in healthy replicating tissues such as hair follicles and the
digestive tract.
An ideal cancer agent would therefore be a drug that can be administered systemically
but then specifically target and destroy cancer cells only, both in the primary tumor and
micrometastases. One approach for increasing tumor specificity is to target proteins or other
molecules expressed or overexpressed in the tumor tissue but not on healthy cells. Due to the
cellular deregulation involved in neoplastic transformation, cancer cells often exhibit a distinct
molecular profile compared to normal tissues. A number of tumor-associated antigens have been
identified including epidermal growth factor receptor-1 and -2 (EGFR and HER2),
carcinoembryonic antigen (CEA), and A33 among others (2-5). While some of these molecules
such as EGFR and HER2 have proliferative or survival roles that can be directly targeted to
prevent tumor growth, others simply act as markers for delivering cytotoxic effectors to the
tumor tissue.
The idea of using a molecule with specific affinity for foreign or diseased cells but not
healthy tissue to deliver cytotoxic modalities dates back to the 19* century and Paul Ehrlich's
vision of a "magic bullet" (6). Over the last 100 years, this idea has come largely to fruition with
the development of monoclonal antibodies. Antibodies are a class of proteins produced by B
cells of the immune system that bind foreign cells and antigens with high affinity and specificity.
In 1975, Kohler and Milstein developed hybridoma technology that allowed for the isolation and
production of single antibody clones (7). Today, monoclonal antibodies with tailored
pharmacokinetic and pharmacodynamic properties can be produced with high affinity binding to
a diverse array of tumor targets.
In their most common format, the IgG, antibodies are 150 kDa globular proteins
consisting of two binding arms and a constant domain (Figure 1.1). Each binding arm includes a
variable domain with 6 peptide loops referred to as complementarity determining regions
(CDRs) that form the site of molecular interaction with the antigen. There is extensive sequence
and structural diversity between the CDRs of different antibody clones, allowing for specific
binding to a diverse array of targets. The constant (Fe) domain of the antibody includes binding
sites for the neonatal receptor FcRn, FcyR receptors, and Clq (8,9). Fc binding to FcRn
mediates salvage from endothelial degradation and reduces antibody clearance form the plasma.
Interactions with FcyR receptors and Clq induce recruitment of immune effector cells and drive
target cell killing through antibody-dependent cellular cytotoxicity (ADCC) and complement-
dependent cytotoxicity (CDC) (6).
Fv-.
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Figure 1.1 - Schematic of IgG antibody structure. Each 150 kDa IgG molecule is a disulfide
locked tetramer comprised of two 25 kDa light chains and two 50 kDa heavy chains. The
tetramer forms two Fab binding arms, each consisting of a variable domain (Fv) which includes
the antigen binding site, and a constant domain (CHI) which provides stability and modularity.
The CH2 and CH3 domains comprise the Fc and are the sites of FcRn, FcyR, and Cl q binding.
To date, there are nine FDA-approved monoclonal antibodies for cancer treatment with
dozens more in clinical trials (10,11). The approved drugs are listed in Table 1.1 along with their
target antigen and approved indication. Six of the antibodies are administered as naked
molecules, two as radiolabel conjugates, and one as a toxin fusion. While most of the molecules
target the cancer cells directly, avastin is an anti-angiogenic agent that reduces blood vessel
growth to prevent the transport of oxygen and nutrients to the tumor.
Table 1.1 - FDA-approved antibodies for oncology
Generic name Trade name Target Indication Effector
Trastuzumab Herceptin HER2 Breast cancer
Rituximab Rituxan CD20 Lymphoma
Cetuximab Erbitux EGFR Colorectal cancer
Bevacizumab Avastin VEGF Colorectal, lung cancer
Alemtuzumab Campath CD52 Chronic lymphocytic leukemia
Pantitumumab Vectibix EGFR Colorectal cancer
Tositumumab Bexxar CD20 Lymphoma 11
Ibritumomab tiuxetan Zevalin CD20 Lymphoma 90Y
Gemtuzumab Mylotarg CD33 Acute myelogenous leukemia Calicheamicin
n - __ - - - -__ __ __ _. :::: -. . .. ............................  I   
1.2 - Engineering antibody properties
While antibody drugs are based on naturally occurring proteins, recombinant protein
engineering approaches can be used to tailor the physical and functional properties of the
molecules. Early therapeutic antibodies were raised in mice and were often immunogenic in
human patients. In clinical trials, a significant fraction of subjects developed human anti-mouse
antibodies (HAMA) leading to toxicity and poor efficacy (12). To make antibodies less
immunogenic, mouse-human chimeras and CDR grafts have been created in which the variable
domain or CDR loops of a mouse antibody are fused to the constant domain and framework
regions of a human antibody (13,14). Similarly, mouse antibodies can be resurfaced by mutating
surface residues in the variable domain framework to their human counterparts (15).
Alternatively, human antibodies can be directly selected from transgenic mice or non-immune
human libraries in phage or yeast (16-18).
Early therapeutic antibodies also suffered from low affinity for the target antigen. As
discussed below, low affinity can limit antibody retention in the tumor, particularly for small,
monovalent antibody fragments. In order to engineer tighter binding antibodies, in vitro affinity
maturation approaches have been developed in which an antibody is mutagenized and variants
with improved binding properties are selected. During selections, the antibody is displayed on a
scaffold such as phage, yeast, or mRNA that links the selected phenotype to the genetic sequence
encoding the antibody (19-21). Through multiple rounds of mutagenesis and selection,
antibodies can be engineered to monovalent dissociation constants in the pM or even fM range.
While the IgG remains the most commonly used therapeutic antibody format, its large
size, slow plasma clearance, and expensive manufacturing in mammalian cells can pose
problems for certain applications. As a result, a number of alternative binding formats have been
engineered with unique pharmacokinetic and structural properties. These include fragments of
the full IgG such as scFvs (MW ~ 27 kDa), Fabs (50 kDa), minibodies (80 kDa), scFv-Fcs (105
kDa), and various scFv and Fab based multimers (22,23). Additionally, a number of non-
immunoglobulin binding scaffolds have been described including DARPins (14 kDa), Fn3
domains (10 kDa), affibodies (6 kDa), and anticalins (20 kDa), each with unique physical
properties (24-27). In particular, DARPin, affibody, and Fn3 domains all lack disulfide bonds,
allowing for intracellular activity and high-yield protein production in bacteria. To extend
plasma lifetime, these small scaffold proteins and antibody fragments can be fused to Fc domains
or linked covalently or non-covalently to albumin (28,29). Antibodies have also been conjugated
to nanoparticles (radius = 10-100 nm) for delivery of a variety of cytotoxic and imaging
modalities. The pharmacokinetics of the IgG molecule itself can be tuned by mutating the Fc
domain to increase or decrease pH dependent binding to FcRn, and thereby increase or decrease
serum persistence (30).
While some antibodies such as anti-EGFR IgGs can directly inhibit proliferative
signaling by preventing ligand binding or receptor dimerization, most therapeutic antibodies rely
on recruiting immune effectors or delivering cytotoxic agents to the tumor. The IgG Fc domain
interacts with FcyR receptors expressed by natural killer (NK) cells, neutrophils, mononuclear
phagocytes, and dendritic cells to initiate antibody-dependent cellular cytotoxicity (ADCC)
responses. By altering the glycosylation structure or amino acid sequence of the antibody Fc
domain, FcyR interactions and ADCC can be increased (31,32). Alternatively, antibodies can be
conjugated to biological toxins, radiometals, or synthetic drugs (33-35). Direct conjugation of
radiometals to the antibody can lead to significant bone marrow toxicity. As a result, pretargeting
strategies have been developed in which a bispecific antibody with affinity for the antigen and a
hapten is administered first, followed by dosing of a radiolabeled hapten at a later time
point (36). For diagnostic imaging applications, a variety of radiometal and near infrared dyes
can be conjugated to antibodies (37).
1.3 - Poor antibody penetration in solid tumors
Despite significant advances and potential for antibody based cancer therapeutics, there
remain numerous challenges. In particular, antibody treatment of solid tumors has proven
difficult with lower response rates typically observed compared to treating blood cancers or
small micrometastatic disease (38). One of the key factors contributing to poor treatment of
solid tumors is limited penetration of antibody drugs into the tumor tissue. Several experimental
models have demonstrated heterogeneous antibody distribution in bulk tumors with
accumulation around the blood vessels and tumor periphery but largely untargeted areas in the
center (Figure 1.2). With the exception of long range radioisotopes and other cytotoxic effectors
that elicit a bystander effect, these untargeted areas remain viable leading to repopulation of the
tumor and potential development of drug resistance.
Figure 1.2 - Examples of heterogeneous antibody targeting in solid tumors. Left: Anti-HER2
scFv (red) penetrates only several cell layers away from a capillary (yellow). 100 ig of scFv
was injected into nephrectomized mice with SKOV-3 xenografts (39). Right: Anti-HER2 IgG
........ . .. ..... . . 
.......
was injected into mice with F2-1282 tumors at a dose of 10 mg/kg. The antibody (green)
accumulates around blood vessels (red) with large portions of the tumor left untargeted (28).
Antibody targeting of solid tumors is a complex process involving distribution and
clearance in the plasma, extravasation across the capillary wall, diffusion and binding in the
tumor tissue, and internalization and catabolism by tumor cells. Due to overexpression of VEGF
and other pro-angiogenic factors, tumors have abnormal vasculature with tortuous structure, poor
blood flow, and regions of high permeability (40). The high permeability leads to plasma protein
leakage, which combined with a lack of functional lymphatics, produces high interstitial fluid
pressure (IFP) (40). This elevated interstitial fluid pressure in turn eliminates convective flow
out of the blood vessels such that antibody extravasation is driven primarily by diffusion (41).
The only significant interstitial convection occurs at the tumor periphery where there is an
outward oozing flow into the surrounding normal tissue.
Due to the limited convection, antibody extravasation is slow and typically the rate
limiting step for tumor uptake. Mathematically, the extravasation rate can be defined as:
d[Ab]tumor 
_ 2PRcap [Abd t_ _ _ _ c a 2 A b A p a s m a
dt RKrogh
where [Ab]mor is the overall antibody concentration in the tumor, P is the capillary permeability,
Reap is the blood vessel radius, RKrogh is the tissue radius surrounding each capillary, [Ab]piasma is
the antibody concentration in the blood stream, and t is the time. This equation is based on
reference (42), modified for consistency with the definition of P from references (43,44).
Similarly, the rate of free antibody diffusion within the tumor tissue can be defined as:
d[Ab]tumor D 2 6[Ab]plasma
dt RKrogh
where D is the interstitial diffusivity and , is the available volume fraction in the tumor. A ratio
of these two rates is defined as the Biot number:
2PRcap Extravasation _ rateBiot = =-~
De Diffusion _ rate
Biot numbers for most antibodies are on the order of 0.005 indicating that interstitial diffusion is
~200 times faster than extravasation, and extravasation is the rate limiting step for tumor uptake.
The amount of antibody at the extravascular surface of the tumor can be estimated as [Ab]sur
Bi-[Ab]piasma.
Rapid antibody binding also contributes to poor tumor penetration due to a "binding site
barrier" phenomenon (45). For most antibodies, binding is much faster than diffusion such that
antibody molecules entering the tumor will bind to the first free antigen they encounter. As a
result, the only way to penetrate deeper into the tumor tissue is to first saturate all antigen in the
preceding layer of cells. It is this phenomenon that produces the sharp boundaries between fully
targeted and fully untargeted cells in Figure 1.2.
While slow extravasation and rapid binding reduce antibody penetration, they alone are
not sufficient to produce the heterogeneous distribution observed in Figure 1.2. If given enough
time and a constant supply of antibody in the blood stream, the binding front will continue to
move through the tumor tissue until all antigen is fully saturated. Rather, the incomplete
targeting is due to antibody loss from the system through two distinct routes. First, following iv
administration, antibodies are cleared from the blood stream, generally through the kidneys for
small fragments or liver for full IgGs. As the plasma concentration drops, there is a decrease in
the diffusive gradient for antibodies entering the tumor. Second, after binding cell-surface
antigens, antibody molecules are internalized and degraded by the tumor cells at a characteristic
rate. At the same time, new antigen molecules come to the surface to bind additional antibodies,
providing a continual metabolic sink for antibody loss.
In effect, the extent of antibody penetration in the tumor is determined by a competition
between the rates of transport (capillary extravasation, diffusion, and binding) compared to the
rates of loss (plasma clearance and cellular internalization). The time scales of these competing
processes can be described mathematically by defining a pair of dimensionless groups: a Thiele
number (<p2) that compares the rate of transport to the rate of loss due to cellular catabolism and a
clearance number (F) that compares the rate of transport to loss due to plasma clearance. The
terms are defined as:
kR 2 ([Ag]y
k, RKrogh 2 Ag endocytic rate
D[Ab]su + Kd transport _rate
2 ([Ag]RKrogh e ) plasma 
_ clearance 
_ rate
A + B  u +Kd) transport _rate
ap
where Kid is the dissociation constant, ke is the net cellular internalization rate, A, a, B, and $ are
terms describing biexponential plasma clearance, and the remaining parameters are defined as
above (46). In order for saturation to occur out to a distance RKogh, both the Thiele number and
clearance number must be less than one (i.e. transport must be faster than both routes of loss).
Importantly, both terms must be satisfied in this model, such that antibody loss by either plasma
clearance or cellular catabolism can be limiting.
A series of experimental studies have been performed in in vitro tumor spheroids to
validate the Thiele number predictions. Thurber et al. showed that anti-CEA antibody fragments
fully penetrated tumor spheroids at a concentration sufficient to achieve the 9p2 < 1 criteria (47).
Ackerman et al. demonstrated that the penetration distance for anti-CEA and anti-A33 antibodies
could be predicted as a function of antigen concentration [Ag] and internalization rate (ke) (48).
Additionally, a number of more detailed mathematical models have been developed which
reproduce many of the same predictions using more rigorous approaches (41,45,49).
1.4 - Tumor targeting parameters
One of the core strengths of the simple time scale model described above is that it clearly
defines a set of parameters describing both the tumor and antibody that are predicted to influence
tumor penetration. Some of the key parameters are highlighted below, along with a discussion of
how they can be manipulated by target selection, dosing regiments, or protein engineering for
improved tumor uptake.
Antibody dose ([A b]pasmo)
The simplest approach for increasing antibody uptake and penetration in solid tumors is
to administer a higher dose of the drug. Mathematical and experimental studies indicate that the
total amount of antibody in the tumor scales linearly with the administered dose at subsaturating
concentrations (50-53). This linear dose dependence for total uptake corresponds to a constant
value when reported as %ID/g. At doses above saturation, antibody uptake will start to plateau
due to a lack of available binding sites and the %ID/g will decrease (52,53). The dose at which
saturation occurs depends on a number of parameters and can vary from 15 pg to several
hundred ptg for mouse xenograft models (52-54). Increasing the antibody dose also increases
antibody penetration and homogeneity in both in vitro spheroids and in vivo xenograft
models (47,55,56). Mathematically, the penetration distance is expected to scale with the square
root of the dose.
Although increasing antibody dose can improve tumor uptake and penetration, there are
limitations due to non-specific toxicity and high background signal. While naked antibodies can
be administered at very high doses with low toxicity (57), the addition of cytotoxic effectors such
as toxins, drugs, or radiolabels significantly lowers the maximum tolerated dose and narrows the
therapeutic window. High doses of radiolabeled antibodies, for instance, can induce significant
bone marrow toxicity (58). For imaging, the high doses produce background signal in the blood
and other well perfused tissues that make it difficult to distinguish the tumor (22). Even the cost
of monoclonal antibodies can be limiting at very high doses (59).
Antigen concentration ([Ag])
High antigen concentrations reduce antibody penetration into the tumor tissue by creating
a larger binding and metabolic sink. In in vitro studies, anti-A33 antibodies penetrate
significantly further into low A33 antigen expressing SW1222 tumor spheroids compared to high
expressing LS174T spheroids (48). In some cases, it may be possible to actively downregulate
antigen levels with crosslinking antibodies or chemotherapeutic agents (60,61). While low
antigen density leads to greater tumor penetration, it also lowers the degree of antibody
accumulation per cell. This may not be a problem for highly toxic molecules such as alpha
emitting radionuclides (62), but it can lead to insufficient cell killing with less potent effectors.
Although not specifically addressed in the time scale model, antigen expression in non-
neoplastic tissue can pose additional problems by causing non-specific toxicity or altering
antibody pharmacokinetics (63,64). Binding to these healthy tissue depots may be reduced by
pre-administering a 'cold' dose of antibody lacking the therapeutic moiety to saturate the
antigen (65,66). Alternatively, MMP activatable antibodies can be developed as discussed in
Chapter 5.
Permeability (P)
As defined by the Biot number, transport across the capillary wall is typically the rate
limiting step for tumor uptake. Due to high interstitial fluid pressure, antibody extravasation is
driven by diffusion through capillary pores. Diffusive permeability is a function of molecular
size such that small antibody fragments and scaffolds extravasate more rapidly across the
vascular wall than full IgGs (44). Due to the negative charge of the capillary endothelium,
positively charged macromolecules also have higher rates of transcapillary flux (67,68).
Another approach for increasing antibody extravasation is to co-administer a second
agent that alters the vascular properties of the tumor to increase diffusive permeability or
convective flow. For instance, systemic administration of IL-2 peptides fused to tumor targeting
antibodies specifically increases the permeability of the tumor vasculature and improves uptake
of subsequently administered drugs (69,70). Similarly, pharmacological agents that increase
blood pressure or reduce interstitial fluid pressure can produce an increase in perfusion and
convection in the tumor (71-73). These effects lead to increased tumor uptake, although the
effect is generally transient. In a different mechanism, anti-angiogenic drugs induce vascular
"normalization" in which the tumor blood vessels take on a more normal physiology with
reduced IFP, increased vessel perfusion, and increased transcapillary convection (74). Vascular
normalization can increase the penetration and efficacy of subsequently administered small
molecules, although the effect on uptake of larger antibodies is still somewhat unclear (75,76).
Antibody extravasation can also be increased by utilizing molecules that are actively
transcytosed across the blood vessel wall through specific interactions with endothelial receptors.
An anti-lung caveolae antibody, for instance, is rapidly and specifically transported into the lung
following systemic administration (77). Similarly, there is evidence that albumin is actively
transcytosed through interactions with endothelial receptors (78,79), which may explain the
impressive tumor uptake of albumin formulated Taxol and antibody fragments fused to albumin
binding peptides (28,80). C-end peptides that bind neuropilin-1 also extravasate and penetrate
tumors effectively, although the mechanism for this effect is somewhat unclear (81).
Void fraction (c), Diffusivity (D)
Both the interstitial void fraction and diffusivity are a function of the physiological
structure of the tumor, in particular the extracellular matrix (ECM), as well as the size and charge
of the targeting molecule (82). Small targeting molecules have faster rates of diffusion and
higher available volume fractions as they are better able to fit through the extracellular matrix
network (83,84). Charge can also impact these parameters as negatively charged species have
lower available volume fractions and slower diffusivity due to electrostatic repulsion from the
negatively charged ECM (85,86). Tumor treatment with collagenase or other enzymes that
degrade the extracellular matrix can lead to increased diffusion and penetration of IgGs (87)
Affinity (Kd, kon, koff)
Following extravasation, antibodies typically bind to the first free antigen they encounter
as binding is faster than diffusion. Once bound, antibodies will be irreversibly immobilized if
their dissociation rate (kog) is slower than internalization (ke), as is generally the case for bivalent
IgGs and other high affinity ligands (88). In contrast, low affinity targeting molecules (kor > ke)
are able to dissociate prior to cellular catabolism and diffuse further into the tumor tissue. As a
result, low affinity antibodies typically have a more homogeneous distribution in the tumor as
demonstrated both mathematically and experimentally (39,49,55,89,90).
Although low affinity antibodies are able to penetrate further into the tumor tissue, it
comes at the cost of decreased antibody loading per cell and potentially decreased tumor
retention. For antibodies approaching homogeneous distribution in the tumor, the fractional
saturation of antigen on each cell can be estimated at steady-state as:
[Ab]suf
koff +ke
ko,
Therefore, the tradeoff is between fully saturating a fraction of cells with a high affinity antibody
or saturating a fraction of antigen on all cells with a low affinity antibody. The relative
effectiveness of each approach will depend on the potency and range of the cytotoxic effector.
Low antibody affinities may also suffer from decreased tumor retention as they are cleared from
the tumor by intravasation while in the unbound state. High affinity antibodies often have higher
levels of total tumor uptake (39,90-93), although this effect plateaus at high affinities and is
dependent on molecular size as described in Chapter 3.
Plasma clearance (A, B, a, fl)
As discussed above, rapid clearance of antibody molecules from the plasma limits
penetration into the tumor by reducing the diffusive concentration gradient. The rate of plasma
clearance is largely a function of size as smaller proteins such as antibody fragments and other
scaffolds are cleared quickly through the kidneys, reducing tumor uptake. There is no exact
cutoff at which kidney clearance becomes dominant, but it is generally significant for molecules
less than 60-70 kDa in size (94). Conjugation of polyethylene glycol (PEG) chains to small
antibody fragments has been shown to increase hydrodynamic radius, reduce plasma clearance,
and increase tumor uptake in a number of studies (95,96). The increase in size, however, also
has negative consequences in terms of reduced permeability, diffusivity, and void fraction as
discussed above. A detailed analysis of these tradeoffs is described in Chapter 3.
IgGs have extended serum persistence due to interactions between the Fc domain and
FcRn receptors on endothelial cells. Following antibody uptake by pinocytosis, the Fc domain
binds to FcRn molecules in a pH dependent manner such that antibodies are trafficked back to
the cell surface, escaping lysosomal degradation (97). Due to this slow plasma clearance profile,
IgGs typically have higher tumor uptake than similarly sized molecules lacking the Fc. Fc
mutations which increase pH dependent binding to FcRn can further increase serum persistence,
while those that disrupt the interactions cause faster clearance (8,98). As predicted by the time
scale modeling, mutations which drive faster clearance lead to lower tumor uptake (99).
Albumin and albumin fusions are also able to bind FcRn in a pH dependent manner (100,101)
leading to extended serum persistence and high tumor uptake (28,102).
Cellular internalization (ke)
Cellular internalization and catabolism of bound antibodies is a significant barrier to antibody
penetration and retention as it creates a constitutive route of antibody loss within the tumor.
Experimental and mathematical studies have demonstrated that antibodies with slower
internalization kinetics penetrate significantly further into the tumor tissue and are retained for a
longer period of time (47-49). The antibody internalization rate depends primarily on the
trafficking kinetics of the target antigen and can vary from half times on the order of minutes for
clathrin coated vesicles to days for tight junction proteins like A33 (103-105). As predicted by
the modeling, antibodies against A33 penetrate significantly farther into tumor spheroids than
those against more rapidly internalized targets (48). Net antibody internalization can also be
reduced by efficient recycling of the antibody back to the cell surface following
endocytosis (106). While slow internalization is desired for improved tumor penetration and
retention, certain cytotoxic effectors such as toxins may require internalization to kill the cell.
These trade-offs between pharmacokinetics and pharmacodynamics have been analyzed by
computational modeling (107).
1.5 - Thesis overview
In this thesis, we attempt to understand and manipulate the transport parameters
described above with the goal of increasing antibody uptake and penetration in solid tumors. In
Chapter 2, we measure the internalization rate (ke) of anti-carcinoembryonic antigen (CEA)
antibodies and demonstrate that this rate can be used to predict tumor penetration in in vitro
tumor spheroids. In Chapter 3, we develop a computational model to predict how antibody size
and affinity impact tumor uptake in vivo. The model analyzes the size-dependent tradeoffs
between diffusivity, void fraction, plasma clearance, and capillary permeability. In Chapter 4, a
novel 79 kDa, monovalent ds(Fv)-Fc antibody fragment is described, and its in vivo targeting
properties compared to an IgG to examine the effects of size and valency. Finally, in Chapter 5,
matrix-metalloproteinase activatable antibodies are engineered as a strategy to avoid binding to
antigen in healthy tissue.
Notes - This chapter was reproduced in part from Thurber GM, Schmidt MM, Wittrup KD.
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv
Drug Deliv Rev. 60:1421-34, 2008.
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Chapter 2 - Kinetics of anti-carcinoembryonic antigen (CEA) antibody internalization
2.1 - Introduction
The transport of antibodies into solid tumors is a complex process involving plasma
clearance, capillary extravasation, interstitial diffusion, antigen binding, and cellular catabolism.
After binding to cell-surface antigens, antibodies are internalized by tumor cells at a constitutive
rate and trafficked to the lysozome for degradation. At the same time, newly synthesized antigen
molecules refill the surface pool, binding and internalizing additional antibody molecules to
produce a constitutive route of antibody clearance. For most cell surface-bound antibodies,
endocytic uptake is more rapid than dissociation such that binding is effectively irreversible and
antibody catabolism is the dominant route of clearance from the tumor (1).
Theoretical analyses suggest that internalization significantly impacts the penetration and
distribution of antibodies in the tumor tissue. According to the timescale model developed by
Thurber et al., incomplete penetration will occur if the rate of antibody loss due to internalization
is faster than the rate of antibody transport. This situation is defined mathematically as a Thiele
number greater than one (<p2 > 1) (2). Cellular internalization also influences tumor retention and
pharmacodynamics of antibody drugs. Slowly internalized antibodies persist at the cell surface
making them ideal agents for ADCC and multi-step pre-targeting therapies. In contrast, rapidly
internalized antibodies may be preferred for delivery of therapeutic moieties that act
intracellularly such as toxins and siRNA.
In order to select antibodies with appropriate trafficking kinetics for a given therapeutic
application, it is important to understand how the physical properties of the antigen and antibody
influence the net internalization rate (ke). In general, the rate of antibody internalization depends
primarily on the cellular localization and trafficking properties of the target antigen. Antigens
associated with clathrin coated vesicles or caveolae are internalized rapidly with uptake half
times on the order of minutes (3). In contrast, bulk non-specific uptake of cell surface markers
occurs with a half time of hours, and tight junction proteins like A33 persist on the surface for
days (4,5). Following endocytosis, antibodies can be recycled back to the cell surface, reducing
the net-internalization rate (6). Alternatively, binding of multivalent antibody constructs alone or
in combination may drive faster antigen internalization through clustering (7).
Carcinoembryonic antigen (CEA) is a 180 kDa GPI linked cell-surface glycoprotein
normally expressed in the fetal gut and on the lumenal surface of the adult colon (8). During
colorectal carcinoma oncogenesis, CEA loses its polarity and becomes overexpressed throughout
the tumor tissue. High levels of CEA expression have also been observed in epithelial tumors in
the lung, breast, thyroid, and ovaries (8). Due to this selective tumor overexpression, antibodies
against CEA have been investigated as targeting agents for a number of imaging and therapeutic
approaches including SPECT and PET imaging, pretargeted radioimmunotherapy, and
ADEPT (9-12).
Although CEA is often referred to as a shed or non-internalizing antigen (13-15), there
have been sporadic reports that antibodies and immunoconjugates against CEA are in fact slowly
internalized by CEA expressing tumor cells (16-18). However, these studies have lacked: (1)
quantitative measurement of the bound antibody internalization rate constant (ke) and (2)
systematic study of how antibody properties such as affinity, stability, and valency influence this
rate. These limitations are addressed in the current study in which the internalization rates of
anti-CEA antibodies are quantified in CEA expressing cell lines using a flow cytometry based
internalization assay. Additionally, the internalization rates of anti-CEA agents differing in
affinity, stability to protease degradation, valency, and target epitope are compared to understand
whether the physical properties of the antibody impact net uptake.
2.2 - Methods
Materials and cell lines
Anti-CEA IgGs M85151 a and M111147 were purchased from Fitzgerald (Concord, MA).
LS174T cells were obtained from ATCC (Rockville, MD). LIM1215 and SW-1222 cells were
the kind gift of the Ludwig Institute. Cells were grown in minimum essential media (MEM)
supplemented with 10% FBS and 1% Penicillin-Streptomyocin. CEA expressing HT-1080 cells
(HT-1080-CEA) were created by transfecting HT-1080 cells with the pIRES-CEA plasmid (kind
gift of Dr. G. Prud'homme, St. Michael's Hospital, Toronto, Canada) using lipofectamine
according to manufacturer's instructions. Transfected cells were selected by growth for 7 days
in MEM with 0.75 mg/mL G418.
Antibody fragment production
Secretion vectors for shMFE and sm3E containing a c-terminal His tag have been described
previously (19). Disulfide stabilized scFvs were produced by mutating residues R44 and G234
to cysteine using the QuikChange kit (Stratagene) according to manufacturer's instructions.
Mutations were confirmed by sequencing. Plasmids were transformed into the YVH10 strain of
yeast using the EZ Yeast Kit (Zymo Research) and plated on SD-CAA media supplemented with
40 ig/mL tryptophan. Individual colonies were grown in 1 L flasks and secretion induced for 48
hours at 37"C as described previously (19). The cleared supernatant was concentrated using
Millipore 10 kDa ultrafiltration membranes and the His-tagged proteins purified using BD Talon
metal affinity resin following the manufacturer's batch-column protocol. Eluted proteins were
further purified by anion exchange chromatography on a Hi-Q column equilibrated with 20 mM
Tris buffer at pH 8.25 and size exclusion chromatography on a Superdex 75 column (GE
Healthcare). Samples were run on a 12% Bis-Tris gel with or without 100 mM DTT and
Coomassie stained to check size and purity. Fab fragments were produced from IgG M85151a
by papain digestion using the ImmunoPure Fab Preparation Kit (Pierce) according to
manufacturer's instructions. Purified antibody fragments were conjugated to Alexa-488
fluorophores using the Microscale Protein Labeling Kit (Invitrogen) following manufacturer's
instructions. Protein concentration and degree of fluorophore labeling were determined from UV
absorbance at 280 and 490 nm as described in the Microscale Kit. The immunoreactive fraction
was estimated by incubating scFvs with a five fold molar excess of soluble CEA (Fitzgerald) and
determining the fraction of antibody that elutes as a complex on size exclusion chromatography.
Linker cleavage and protease stability
The (Gly4Ser)3 linker connecting the VH and VL domains of the scFvs was cleaved by incubating
the antibody fragments with 0.02 Units/mL subtilisin in digestion buffer (20 mM Tris-HCl, 5
mM calcium chlorate, pH 7.5) for 90 minutes at 374C. Digested samples were run on a 12% Bis-
Tris gel with or without 100 mM DTT and Coomassie stained. For functional protease stability
assays, Alexa-488 labeled scFvs were incubated with increasing concentrations of subtilisin in
digestion buffer for 60 minutes at 37*C. Trypsinized LS174T cells were labeled with the
digested antibody fragments at subsaturating concentrations for 20 min on ice and mean cellular
fluorescence measured on an EPICS Coulter XL flow cytometer (Beckman Coulter, Inc.)
Cell-surface binding
Trypsinized LS 1 74T cells were fixed with Cytofix Buffer (BD Biosciences) for 20 minutes at
4"C to prevent antibody trafficking. For Kd measurements, fixed cells were incubated with
Alexa-488 labeled antibodies or antibody fragments at a range of concentrations for 16-20 hours
at 370C. To avoid antibody depletion effects, a 10 fold molar excess of antibody over antigen
was maintained throughout. Labeled cells were washed twice with PBS + 0.1% BSA, and the
mean Alexa-488 cellular fluorescence measured on an EPICS Coulter XL cytometer. The
normalized signal was fit to the equation MFU = Bmax ([Ab]/([Ab]+Kd)) to determine the Kd.
For koff measurements, fixed cells were labeled overnight with saturating concentrations of
Alexa-488 conjugated scFvs. Cells were washed and resuspended at 370C in PBS-BSA
containing 100 nM unlabeled sm3E to prevent rebinding of dissociated antibodies. At each time
point, cells were washed and the mean fluorescence quantified by flow cytometry. Fluorescence
values were normalized by the signal at t = 0 and fit to an exponential decay to determine the kog.
The number of antibodies bound per cell at saturation was determined by labeling cells with
saturating concentrations of Alexa-488 conjugated antibodies or antibody fragments and
converting the fluorescence intensity to a number of molecules using Alexa-488 calibration
beads and the calculated number of fluorophores per antibody.
Net antibody internalization assays
LS 1 74T cells were subcultured into 96 well plates at a concentration of 105 cells per well and
allowed to adhere for 12-16 hours. After washing cells once in media, 125 pL of Alexa-488
conjugated antibodies or antibody fragments at a concentration of 20 nM in MEM + FBS was
added to each well. Cells were incubated at 370C in the continuous presence of the labeled
antibodies. At each time point, plates were chilled, wells washed twice in PBS-BSA, and cells
lifted by incubating with 200 ptL cell dissociation buffer (Gibco) for 10 minutes on ice.
Dissociated cells were transferred to microfuge tubes by pipetting and sedimented at 14000 x g.
Cell pellets were resuspended in PBS-BSA with or without 25 ig/mL anti-Alexa-488 quenching
IgG (Molecular Probes) for 25 minutes on ice. The mean fluorescence of the surface quenched
and unquenched cells were measured on an XL cytometer and used to calculate the relative
amounts of surface and internal fluorescence as described previously (6). In brief, surface
fluorescence was determined as (unquenched MFU - quenched MFU)/s where s is the quenching
efficiency determined by comparing the quenched and unquenched signals of cells that had been
labeled briefly on ice to prevent internalization. The internal fluorescence was then calculated as
Total MFU - Surface MFU. Non-specific internalization of antibodies due to fluid phase uptake
was measured using cells where the CEA was pre-blocked with unlabeled antibody and
subtracted from the internal signal. The corrected internal MFU values were plotted against the
integral of the surface fluorescence determined using the trapezoidal rule and fit to a linear curve,
the slope of which is the internalization rate ke (3). scFv uptake experiments in the LIM1215,
SW-1222, and HT-1080-CEA cell lines were performed essentially as described above except
trypsin-EDTA was used in place of cell dissociation buffer to lift the cells from the plates at each
time point.
Surface decay
LS 1 74T cells subcultured in 96 well plates as above were surface labeled with saturating
concentrations of Alexa-488 labeled sm3E, ds-shMFE-M, or M85151 a IgG for 1 hour on ice.
Unbound antibody was washed from each well and cells were incubated in media at 37*C. At
each time point, cells were chilled and transferred to microfuge tubes as described above. Cells
were then surface labeled on ice with PE conjugated secondary and tertiary antibodies to
determine the amount of anti-CEA antibody remaining on the surface. Goat anti-mouse PE (1:50
dilution) was used for M85151 a and anti-His biotin (1:70 dilution) followed by streptavidin-PE
(1:100 dilution) for the scFvs. Cells were analyzed by flow cytometry to measure the 488 signal
(total cell associated antibody) and PE signal (surface accessible antibody).
CEA downregulation
LS174T cells subcultured into 96 well plates as above were incubated at 37"C in media with or
without 50 nM unlabeled anti-CEA antibodies or antibody fragments. At each time point, cells
were chilled, washed twice with cold CO2 independent media, and labeled for 40 minutes on ice
with 20 nM of a non-competitive Alexa-488 labeled anti-CEA antibody. Cells were then
washed, lifted with cell dissociation buffer, and analyzed by flow cytometry as above. The
Alexa-488 signal of cells incubated with unlabeled antibody was normalized by the signal of
cells incubated with media alone to determine the degree of antigen downregulation.
Biotinylated CEA turnover
LS 1 74T cells were subcultured into 12 well plates at a density of 2 x 106 cells per well and
grown for 24 hours at 37*C. Cells were washed and surface biotinylated with 1 mg/mL NHS-
SS-biotin (Pierce) in PBS, pH 8.0. The labeling reaction was quenched after 30 minutes by the
addition of 100 mM Tris-HCl. The cells were then washed twice in media and incubated at
37*C. At each time point, cells were placed on ice, washed twice with PBS-BSA, and incubated
in 500 tL of ice cold lysis buffer for 10 minutes. The cell lysate was cleared by centrifuging at
14000 x g for 15 minutes and biotinylated proteins pulled down with streptavidin resin (Pierce).
The bound proteins were washed and eluted by cleaving the disulfide linker with 100 mM DTT.
Eluted samples were run on a 4-12% SDS-PAGE gel, transferred to a nitrocellulose membrane,
and blotted for CEA using M85151a IgG (1:1000 dilution) and goat anti-mouse-HRP secondary
(1:1000 dilution). Band intensities at each time point were quantified using QuantityOne
software (Bio-Rad) and normalized by the band intensity at time zero.
2.3 - Results
The internalization rate of cell bound antibodies and antibody fragments is predicted to
significantly alter the microdistribution, surface accessibility, and retention time of these
molecules in tumor tissue. Therefore, we set out to quantitatively measure the internalization of
antibodies and antibody fragments directed against the common tumor target CEA. Furthermore,
we examined how antibody parameters such as affinity, stability to protease digestion, valency,
and target epitope influence these internalization rates.
2.3.1 - scFv production
As a model system to examine the effect of antibody properties on cellular uptake, we
developed a series of anti-CEA single-chain variable fragments (scFvs) with differences in
affinity, stability to protease degradation, and valency. scFvs are -27 kDa antibody fragments
consisting of the VH and VL domains of an IgG connected by a peptide linker. Previous affinity
maturation work resulted in two scFvs sm3E and shMFE that bind to the same epitope on CEA
with a nearly 300 fold difference in affinity (sm3E Kd = 30 pM, shMFE Kj = 8.5 nM) (19). To
make fragments with increased stability, cysteine residues were inserted into the VH and VL
domains of the proteins to form an interdomain disulfide bond. The formation of this
interdomain disulfide has been shown to increase the protease and thermal stability of
scFvs (20,21). Additionally, the disulfide stabilized scFvs (ds-scFvs) are secreted in yeast as a
mix of disulfide locked monomers (ds-scFv-M) and dimers (ds-scFv-D) which can be separated
to provide fragments with differences in valency.
Secreted antibody fragments were concentrated and purified at a final yield of 0.5-1
mg/L. All proteins matched expected sizes when run on non-reducing and reducing SDS-PAGE
gels and demonstrated purity greater than 99% (Figure 2.1A). The slightly increased mobility of
the disulfide stabilized monomers compared to the native scFvs under non-reducing conditions is
indicative of interdomain disulfide bond formation, which produces a more compact denatured
structure. Formation of the interdomain disulfide was further confirmed by proteolytically
cleaving the peptide linker connecting the VH and VL domains of the scFvs and assaying protein
mobility on SDS-PAGE. Following linker cleavage, the VH and VL domains of the disulfide
stabilized scFvs are held together under non-reducing conditions by the interdomain disulfide
bond (Figure 2.1B).
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Figure 2.1 - Antibody fragment production in yeast. A: SDS-PAGE analysis of scFvs under
non-reducing (top) and reducing (bottom) conditions. Purified scFvs were run on a 12% Bis-Tris
gel with or without 100 mM DTT. All antibody fragments run at their expected molecular
weights and are -99% pure. B: Cleavage of peptide linker suggests that interdomain disulfide
bond is formed in ds-scFvs. The peptide linker connecting the VH and VL domains of each scFv
was cleaved with low concentrations of subtilisin. Following linker cleavage, the two domains
of the disulfide stabilized fragments are held together under non-reducing conditions by the
interdomain disulfide bond such that the protein runs at -27 kDa.
2.3.2 - scFv binding and stability
Antibody affinity and avidity was assessed by measuring the binding of Alexa-488
conjugated antibody fragments to fixed LS174T cells (Table 2.1). Both disulfide locked
monomers exhibit dissociation constants (30 pM for ds-sm3E-M and 9.2 nM for ds-shMFE-M)
similar to those measured previously for sm3E and shMFE by yeast surface display (19). In
contrast, the bivalent molecule ds-shMFE-D has a roughly 100 fold higher apparent affmity (85
pM) than its monomeric counterpart due to avidity from bivalently binding to cells.
Interestingly, the non-disulfide stabilized shMFE also exhibits a higher affinity than ds-shMFE-
M, likely due to the formation of non-covalent dimers in solution. The formation of such
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reversible dimers has been observed previously for a closely related scFv MFE-23 (22). sm3E
and ds-sm3E-D demonstrate less significant increases in apparent affinity compared to their
monomeric counterpart ds-sm3E-M, although this is likely due to the high affinity of the
monovalent interaction rather than an absence of bivalent binding. Off-rate measurements in the
presence of unlabeled competitor support the conclusion that both disulfide stabilized dimers and
native scFvs bind to the cell bivalently as their dissociation constants were -2-3 fold slower than
those of the disulfide locked monomers (Table 2.1). In the absence of competitor, dissociation
rates for these bivalent antibody fragments would be significantly slower due to continued
rebinding of the two arms (23). The high affinity scFvs were also >95% functional as
determined by soluble CEA binding assays as described in the materials and methods (data not
shown).
The contribution of the interdomain disulfide to functional scFv stability was assessed by
incubating the antibody fragments in increasing concentrations of the protease subtilisin, then
measuring binding to LS 174T cells at subsaturating concentrations. As expected, the disulfide
stabilized proteins displayed significantly higher binding activity following protease treatment
than the native scFvs suggesting improved stability (Figure 2.2). As a whole, the in vitro cell
binding assays confirmed that the secreted scFvs exhibited the expected differences in affinity,
stability to protease digestion, and valency, and were therefore a useful model system for the
effects of these parameters on net internalization.
scFv Kd (pM)
sm3E 26+ 4
ds-sm3E-M 30 ± 5
ds-sm3E-D 9.6 ± 0.7
shMFE 160 24
ds-shMFE-M 9300 3300
ds-shMFE-D 85 ± 5
Table 2.1 - Binding constants for Alexa-488 label
LS 174T cells
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Figure 2.2 - The interdomain disulfide bond
increases functional protease stability of ds-scFvs.
Alexa-488 labeled anti-CEA scFvs with or without
the interdomain disulfide bond were incubated with
increasing concentration of subtilisin and used to
label fixed LS 1 74T cells at subsaturating
concentrations. The disulfide stabilized fragment
maintains significantly greater binding activity in
the presence of the protease.
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2.3.3 - Internalization rate constant (ke) measurements
The cellular net internalization rate constant (ke) of each scFv was assayed using a
fluorescence quenching protocol, similar to one described previously for Herceptin endocytic
trafficking (6). Adherent LS174T cells were incubated at 37*C in the continuous presence of
Alexa-488 labeled antibody fragments. At each time point, cells were chilled, lifted, and 2 of
the cells surface quenched with anti-Alexa-488 IgG. The efficiency of surface quenching was
independently measured for each antibody fragment using cells that had been labeled briefly on
ice to prevent internalization, and ranged from 84-91%. The fluorescence intensity of quenched
and unquenched samples was quantified by flow cytometry and the surface and internal
fluorescence calculated as described in materials and methods. In general, the surface
fluorescence increases over the first hour and then plateaus as antibody binding reaches
equilibrium, while the internal fluorescence continues to increase over time as antibodies are
endocytosed and the fluorophores retained in the cell (Figure 2.3A). Unlike fluorescein, Alexa-
488 fluorescence is not quenched at intracellular pH so there is no significant decrease in signal
intensity of endocytosed fluorophores. Non-specific uptake was measured using cells that had
been pre-blocked with unlabeled sm3E and was generally found to be low at the experimental
antibody concentrations.
Internalization rates were derived from the quenched fluorescence data by plotting the
internal fluorescence against the time integral of the surface fluorescence and applying a linear
fit (Figure 2.3B). Uptake rates were measured in this manner for all scFvs and are reported as
internalization half times in Figure 2.4 (where ti, = ln(2)/ke). In general, internalization of the
anti-CEA scFvs is slow with half times ranging from 10-16 hours. Surprisingly, neither antibody
affinity, stability to protease digestion, nor valency significantly affect the internalization rate of
bound antibody fragments in this assay as there is no significant difference in uptake half times
among the scFvs.
The fluorescence quenching protocol was also used to measure the uptake rates of a pair
of commercially available anti-CEA IgGs M111147 and M85151a. These antibodies bind to
different (non-competing) epitopes on CEA from the scFvs and each other (data not shown) and
have functional affinities of 70 pM for M111147 and 7 pM for M85151a as measured by cell
surface titration. While MI 11147 was internalized with a half time of 13 hours, similar to the
scFvs, M8515 1a was taken up significantly faster with a half time of 5 hours (Figure 2.4A). A
monovalent Fab fragment of M85151 a with a functional affinity of 2.5 nM was internalized with
a net uptake rate (t12 - 14 hours) significantly slower than the IgG, suggesting that the bivalency
of the full antibody is necessary for its faster uptake (Figure 2.4A).
The effect of cell type on anti-CEA antibody fragment internalization was assessed by
measuring the internalization of the high affinity scFv ds-sm3E-M in 3 additional cell lines.
LIM1215 and SW-1222 are colon carcinoma cell lines that express CEA at lower levels than
LS174T, while HT-1080-CEA is a fibrosarcoma cell line transfected with a CEA expression
plasmid resulting in antigen overexpression. LIM1215 and SW-1222 internalized ds-sm3E-M
with half times of 11.5 and 17.2 hours, respectively, both similar to the 15.3 hour half time
measured in LS174T cells (Figure 2.4B). In contrast, HT-1080-CEA cells internalized the scFv
at a significantly faster rate with a net uptake half time of 4 hours.
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Figure 2.3 - Net internalization assay. A: LS174T cells were continuously incubated at 37"C in
the presence of Alexa-488 labeled antibodies. Total cellular fluorescence was measured at each
time point by flow cytometry and the internal and surface fractions determined by surface
quenching with an anti-Alexa-488 IgG. Non-specific uptake was measured by pre-blocking
CEA with a 100 fold excess of unlabeled antibody. Data pictured is for an individual experiment
with ds-sm3E-D. B: Derivation of internalization rate ke. Internal fluorescence values are
plotted against the integral of the surface fluorescence determined by the trapezoidal rule and fit
to a linear curve. The slope of the linear fit is the internalization rate ke. Data points pictured are
pooled from 4 separate experiments with ds-sm3E-D.
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Figure 2.4 - Net internalization rates. A: Internalization rates were determined for all antibodies
in LS 174T cells and plotted as a half time for antibody net uptake. With the exception of IgG
M8515 1a, all tested antibodies are internalized slowly with a half time of 10- 16 hours. IgG
M85151a is internalized significantly faster with a half time of ~5 hours (p < 0.001). Half times
are the average of 3-6 individual experiments for each antibody and error bars are SD. B:
Cellular internalization rates of Alexa-488 labeled ds-sm3E-M were determined in multiple CEA
expressing cell types. Colon carcinoma lines LIM 1215 and SW- 1222 internalize the scFv at
similar rates as LS 174T, while HT- 1080 fibrosarcoma cells transfected with a CEA expression
plasmid internalize the antibody fragment more rapidly.
2.3.4 - Antibody surface decay
Antibody internalization was also measured in the context of a pulse labeling experiment
that better simulates the retention phase of tumor targeting. LS 174T cells were surface labeled
on ice with Alexa-488 conjugated anti-CEA scFys or IgG, washed to remove unbound
molecules, and incubated at 370C. At each time point, cells were surface labeled on ice with
PE-conjugated anti-mouse or anti-His secondary antibodies, and the 488 and PE signals
measured by flow cytometry to determine the total cell associated and surface antibody,
respectively. The high affinity scFv sm3E exhibits slow decay of both the total antibody and
surface accessible fluorescence (Figure 2.5A). The decrease in total signal may be due to
antibody dissociation, antigen shedding, or cellular efflux of degraded fluorophore. The surface
signal drops faster than the total signal over the course of several hours, indicating a slow
internalization of scFv in rough agreement with the ke values measured in the continuous uptake
experiments. In contrast to sm3E, the surface level of M85151a IgG drops rapidly over the first
3 hours to approximately 50% of its initial level while the total signal remains virtually
unchanged, suggesting a more rapid internalization as observed in the continuous uptake
experiments (Figure 2.5B). The slow loss of Alexa-488 signal from the rapidly internalized IgG
suggests that intracellular antibody degradation and cellular efflux of degraded fluorophore is
relatively slow and the more rapid decrease in total signal for sm3E is primarily driven by scFv
dissociation or antigen shedding. The low affinity scFv ds-shMFE-M dissociates completely
from the cell surface before any significant internalization takes place (data not shown).
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Figure 2.5 - Antibody surface decay. LS174T cells were surface labeled with Alexa-488
conjugated antibodies on ice then chased at 37*C. At each time point, cells were surface labeled
with a PE conjugated secondary antibody and the Alexa-488 signal (total antibody) and PE
signal (surface antibody) measured by flow cytometry. The difference between the total and
surface antibody pools represents internalized antibodies. The high affinity scFv sm3E (A) is
slowly endocytosed from the cell surface while IgG M85151 a (B) displays a more rapid decrease
in surface antibody levels due to faster internalization.
2.3.5 - CEA downregulation and surface antibody levels
Antibodies against EGFR and other cell surface proteins have been shown to
downregulate surface levels of their target antigen following binding which may have significant
effects on antibody microdistribution and pharmacodynamics (7,24). To determine if anti-CEA
antibodies are also capable of downregulating their target antigen, LS 174T cells were incubated
with saturating concentrations of unlabeled antibodies or antibody fragments at 37"C and the
surface CEA concentration determined at each time point by labeling the cells on ice with an
Alexa-488 labeled non-competitive anti-CEA antibody. Both the monovalent and bivalent high
affinity scFvs (ds-sm3E-M and ds-sm3E-D), as well as the slowly internalized IgG MI 11147,
have no effect on the surface levels of CEA (Figure 2.6). In contrast, incubation with the rapidly
internalized IgG M85151 a induces a 20% decrease in surface CEA levels that is sustained to 5
hours. This downregulation is not observed when the cells are incubated with a monovalent Fab
fragment of the antibody suggesting that the activity is valency dependent.
Antigen concentration and the number of antibody molecules bound per cell at saturation
may also influence the tumor microdistribution of antibodies (25,26). To quantify these
parameters, the cellular fluorescence of LS 174T cells labeled with saturating concentrations of
Alexa-488 labeled antibodies or antibody fragments was measured and converted to a number of
bound molecules per cell using fluorescent calibration beads. As seen in Figure 2.7A, -400,000
molecules of the monovalent scFv ds-sm3E-M are bound to each cell at saturation, while the
scFv dimer ds-sm3E-D and IgG M1 11147 saturate the cell with -40% fewer molecules due to
bivalent antigen binding. Interestingly, both the IgG and Fab versions of M85151a bind with
approximately twice as many molecules per cell at saturation as the other antibodies of
equivalent valency. The greater cell surface binding at saturation for M85151a compared to
M1l11147 was also observed on HT-1080-CEA cells (Figure 2.7B) while neither antibody binds
HT-1080 in the absence of CEA expression suggesting that M85151a's higher cell labeling is
mediated by interactions with CEA and is not due to binding other proteins on the cell surface.
The difference in cell binding stoichiometry is also not due to heterogeneous antigen that is
partially unreactive with the scFvs and M1 11147 since >95% of soluble CEA elutes as a
complex on size exclusion chromatography when incubated with an excess of any of the tested
antibodies (data not shown). One potential explanation for the two fold greater cell binding of
M85 151 a is the possibility that this antibody binds to two different epitopes on each CEA
molecule (see discussion).
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Figure 2.7 - Surface CEA binding stoichiometry. A: LS174T cells were labeled to saturation
with Alexa-488 conjugated antibodies and the number of molecules bound per cell calculated as
described in materials and methods. Both the IgG and Fab versions of M85151a have
approximately twice as many molecules bound at saturation as other antibodies of equivalent
valency. All measurements done in triplicate and error bars are SD. B: HT-1080 and HT-1080-
CEA cells were labeled with M111147 IgG (grey bars) or M85151a (black bars). The amount of
bound antibody was determined with a goat-anti-mouse-488 secondary. Approximately twice as
many M8515la molecules bound to the HT-1080-CEA cells as compared to M1 11147.
2.3.6 - Metabolic turnover of CEA
Finally, we examined the metabolic turnover of the target antigen CEA in the absence of
antibody using a biotinylation pulse-chase assay. LS 1 74T cells were surface biotinylated with a
NHS-SS-biotin reagent, washed, and incubated at 370C. At each time point, cells were lysed,
biotinylated proteins affinity purified with streptavidin resin, and eluted samples analyzed with
anti-CEA western blots. The band intensity of the purified samples decreases over time as
biotin-pulsed CEA molecules are catabolized by the cells (Figure 2.8A). Band intensities were
quantified and fit to an exponential decay to derive a rate of CEA turnover (Figure 2.8B). Using
this assay, the half time for CEA turnover was determined to be 15 hours. This value is
approximately equal to the rate of antibody internalization (Figure 2.4), suggesting that the
metabolic turnover of CEA drives antibody uptake and that the antibodies themselves do little to
modulate this rate - with the exception of IgG M85151 a.
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Figure 2.8 - Metabolic turnover of CEA. Cell surface proteins were pulsed with biotin using an
NHS-SS-biotin reagent and chased at 374C. At each time point, cells were lysed, biotinylated
proteins pulled down with streptavidin resin, and the pulldown blotted for CEA as described in
materials and methods. Band intensities were normalized to the signal at time zero and fit to a
negative exponential. A: Western blot from a single experiment. B: Pooled data from 3 separate
experiments fit to a negative exponential. Each symbol represents a different experiment. CEA
is degraded with a half time of 15 hours, similar to the internalization rate of the anti-CEA
antibodies.
2.4 - Discussion
Theoretical analyses of antibody transport in solid tumors suggest that cellular
internalization and catabolism of bound antibodies significantly retards penetration of these
drugs into the tumor. In order to test these predictions using CEA-specific antibodies as a model
system, the rates of antibody and antibody fragment internalization by CEA expressing tumor
cells were measured. Fluorescence measurements using flow cytometry provided a quantitative
and facile method for measuring trafficking kinetics that was higher throughput than imaging
approaches and avoided artifacts of incomplete antibody stripping observed with acid washing
protocols.
With the exception of IgG M85151 a (discussed below), all anti-CEA antibodies and
antibody fragments tested were internalized in LS 1 74T cells slowly with uptake half times of 10-
16 hours. This time scale is consistent with the metabolic turnover rate of CEA in the absence of
antibody (t12 ~15 hours) suggesting that the antibodies are taken up passively with the antigen
and do little to drive or modulate this uptake. The tested antibodies and antibody fragments have
no effect on surface levels of CEA following binding, which is also consistent with a passive
uptake mechanism. Since CEA is a GPI linked protein with no cytoplasmic or transmembrane
protein domains, the observed uptake is likely the result of bulk membrane turnover rather than
specific protein mediated pathways (8). Such non-specific trafficking of CEA is consistent with
immunofluorescent microscopy experiments demonstrating that internalized anti-CEA scFvs
colocalize partially but incompletely with markers of multiple endocytic pathways (27). Similar
slow metabolic turnover has been observed for other antibodies targeting non-receptor cell
surface antigens (4).
Slow cellular uptake of the high affinity anti-CEA scFv ds-sm3E-M was also observed in
two additional colon carcinoma cell lines, LIM1215 and SW-1222. In contrast, uptake was
significantly faster (t 12 ~ 4 hours) in a fibrosarcoma cell line HT-1080 transfected with a CEA
expression plasmid. It is unclear if this faster uptake is due to greater overall cell surface
turnover in this cell line or some finction of the artificial CEA overexpression.
Cellular trafficking studies in other systems suggest that the affinity and valency of
soluble ligands or antibodies may alter cellular uptake rates by influencing the fraction of
molecules that are recycled to the cell surface following endocytosis, or by altering antigen
clustering dynamics on the cell surface (28,29). In the case of the anti-CEA scFvs examined
here, however, no significant difference in the net uptake constant (ke) was observed for
molecules with a range of affinity, stability to protease digestion, and valency. The lack of an
affinity dependency may suggest that CEA binding occupancy in the endosome has little effect
on the fraction of antibodies that are recycled versus degraded, or alternatively, that both the high
and low affinity scFvs are able to maintain antigen binding in the endosome due to the high
concentration of CEA. Similarly, the equivalent uptake of the monovalent and bivalent scFvs
suggests that crosslinking of two CEA molecules on the cell surface has little effect on the
antigen's distribution or trafficking. This result is consistent with previous observations that
bivalent binding of IgGs against folate receptor, another GPI-linked protein, was insufficient to
drive receptor clustering on the surface or increase uptake (30).
Although affinity and valency have little impact on the uptake constant (ke) of anti-CEA
antibodies, they may still influence the total amount of internalized antibody which depends on
both ke and the amount of antibody bound (d[Ab]intema/dt = ke* [Ab]boud). This distinction is
clearly observed with the behavior of the low affinity scFv ds-shMFE-M in the continuous
uptake and surface decay experiments. While ds-shMFE-M is internalized when continuously
incubated with the cells at a 20 nM concentration, it dissociates from the cells prior to
internalization in the surface decay assay. Both of these cases are relevant to in vivo tumor
targeting. The continuous uptake experiments are similar to the loading phase of tumor targeting
where a high plasma concentration maintains a sufficient antibody concentration in the tumor to
drive binding and internalization, while the surface decay assay represents the retention phase
when antibody clears from the plasma and tumor. In contrast to the low affinity case, the high
affinity and bivalent antibodies have dissociation rates (kog) slower than the internalization rate
(ke) such that binding will be essentially irreversible in both targeting regimes (4).
Unlike the remainder of the tested antibodies, IgG M85151 a exhibited a distinct
trafficking profile with a significantly faster net uptake rate (t 2 5 hours) and the ability to
downregulate surface CEA. These properties were both valency dependent, as a monovalent Fab
fragment of M85151a was internalized slowly and had no effect on surface CEA. Both the
M85151 a IgG and Fab also bind with approximately twice as many molecules per cell at
saturation as compared to other antibodies of equivalent valency. One potential explanation for
this two-fold higher cell binding stoichiometry is the possibility that these antibodies bind to
more than one epitope per CEA molecule. Monoclonal antibodies capable of binding multiple
epitopes per CEA molecule have been reported previously, a phenomenon attributed to the high
sequence homology of repeat domains within the antigen (31-33). If M85151a does in fact bind
two epitopes per CEA molecule, it may also provide a mechanism for the faster uptake. Bivalent
antibodies that bind to a single epitope per antigen can only crosslink two molecules. In contrast,
a bivalent molecule that binds more than one epitope per molecule may be able to crosslink
larger clusters of antigens. Previous studies have demonstrated that the formation of large
clusters of GPI linked proteins can increase antigen localization in caveolae, as well as drive
greater antigen internalization and downregulation (7,30,34).
Although the experiments presented here indicate that the internalization of anti-CEA
antibodies and antibody fragments in LS 1 74T cells occurs slowly, this rate is sufficient to
significantly impact antibody distribution and retention in the tumor. Thurber and Wittrup have
shown that anti-CEA scFvs are able to penetrate significantly farther into LS 174T spheroids
when incubated at 20*C vs. 370C due to reduced cellular internalization (35). Similarly,
Ackermann et al. demonstrated that the slowly internalized IgG MI 11147 penetrates
significantly farther into LS174T spheroids than the rapidly internalized IgG M85151a (26). The
difference in penetration distance can be quantitatively predicted from the ke values and cell
surface binding stoichiometry measured here.
Based on these results and other computational predictions, we suggest that antibodies
with slow cellular internalization rates should have advantages for most tumor targeting
applications due to their improved penetration and retention in the tumor (with the exception of
immunotoxins and antibody-drugs that must be internalized to be cytotoxic (36)). In some cases,
it may be possible to engineer more slowly internalized antibodies by either selecting for proteins
that are efficiently recycled following endocytosis or by using monovalent antibodies that avoid
faster uptake due to antigen clustering. Alternatively, antibody internalization may be reduced
by targeting antigens with slower metabolic turnover. One promising target is the colorectal
cancer marker A33 which has extended cell surface persistence due to interactions at the tight
junction (5).
Notes - This chapter was reproduced in large part from Schmidt MM, Thurber GM, Wittrup KD.
Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency,
and stability. Cancer Immunol Immunother. 57:1879-90, 2008.
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Chapter 3 - Modeling the Effects of Size and Affinity on Tumor Targeting
3.1 - Introduction
To date, IgG monoclonal antibodies have been the dominant format for tumor targeting
due to their high functional affinity for the target antigen and favorable pharmacokinetic profile.
However, the limitations of these molecules, most notably expensive production in mammalian
cell lines and relatively large size, have led to research into alternative targeting agents. Today,
there are a number of antigen binding formats with unique physical properties being developed
as tumor imaging or therapeutic agents. Initial development of novel targeting agents focused on
making smaller fragments of the full IgG that retain antigen binding properties, including 27 kDa
scFvs, 50 kDa Fabs, 80 kDa minibodies, and various scFv and Fab based multimers (1). More
recently, alternative binding scaffolds including 14 kDa DARPins and 7 kDa affibodies have
been engineered that bind antigens with high affinity despite their small size (2,3). At the other
end of the size spectrum, nanoparticles and liposomes with molecular radii ranging from 10-100
nm have been developed that incorporate targeting, imaging, and therapeutic functionalities (4).
Chemical conjugation approaches such as PEGylation have allowed for further tailoring of
molecular size (5).
While these diverse molecules vary in a number of properties including valency,
geometry, stability, and surface charge, the most obvious difference is a wide range of molecular
radii. Despite several experimental comparisons, however, the exact effects of these size
differences on tumor targeting remain unclear. This confusion arises largely from the fact that
size influences several distinct transport parameters involved in tumor uptake including
permeability across the tumor capillary wall (P), diffusivity within the tumor interstitium (D),
available volume fraction in the tumor (&), and rate of plasma clearance (kciear) (5-8). These
parameters counteract each other in a manner that makes predicting the effects of size difficult a
priori. For instance, small molecules have increased rates of transport across the capillary wall
and within the tumor but are also rapidly cleared from the plasma, eliminating the diffusive
gradient into the tumor. In contrast, large molecules are cleared from the blood more slowly, but
simultaneously suffer from slower rates of transcapillary and interstitial transport.
Due to the complexity of these tradeoffs, computational tools are needed to accurately
predict the effects of molecular size on tumor transport. Such models have previously been used
to predict antibody microdistribution and macrodistribution within tumors and examine the effect
of parameters such as tumor physiology, dose, binding affinity, and antigen turnover (9,10).
Here we extend these models to predict the magnitude and specificity of tumor uptake for
molecules covering the continuum of sizes from small peptides to liposomes by incorporating
derived empirical relationships for the effect of hydrodynamic radius on the parameters P, D, s,
and kcie&. Our predictions are consistent with published biodistribution studies targeting HER2
expressing xenografts in mice, as well as clinical data from targeting CEA expressing tumors in
humans, and shed light on the complex interplay of size and binding affinity in tumor targeting.
3.2 - Methods
Previously reported experimental measurements of capillary permeability (P), interstitial
diffusivity (D), available volume fraction (z), and plasma clearance (kciear) for molecules of
various sizes in tumor tissues were collected from the literature (Appendix B). The data sets
include studies on proteins, small molecule tracers, dextrans, PEG chains, and liposomes,
primarily in mouse xenograft models. Mathematical equations describing the relationship
between these parameters and molecular radius (Rmoi) over a broad continuum of sizes were
derived by fitting structural and empirical models of the capillary wall, tumor interstitial space,
and renal and non-renal routes of plasma clearance. Implicit in all of these descriptions is the
assumption that these are hydrophilic molecules that are not sequestered in membranes or fatty
tissue. Fitting was performed using the non-linear least squares method in MATLAB.
The effect of molecular radius on diffusivity (D) and available volume fraction (s) within
the tumor can be described by modeling the tumor interstitial space as a series of small and large
right circular cylindrical pores. Using this framework, the molecular diffusivity within each pore
can be described as Dpore = Dfree * (Dpore/Dfree), where Dfree is the diffusivity of the molecule in
solution (cm 2/s) and Dpore/Dfree is the fractional reduction in free diffusion within the pores (11).
Dfree can be estimated using the relationship Dfree = (3 x 10-6 cm 2/s)/Rmoi, where Rmoi is the
molecular radius in nm. Dpore/Dfree can be solved as:
Dpore (1-2.105A + 2.0865A3 -1.7068A' + 0.72603A6) (3.1)
Dfree (1-0.75857A')
for values of X < 0.6 where X is defined as the ratio of molecular radius (Rmoi) to pore radius
(Rpore) (11). For 0.6 < k < 1, numerical values of Dpore/Dfree were determined from previously
described lookup tables (12). For A > 1, Dpore/Dfree = 0. To account for diffusion through small
and large pores in the tumor, diffusivity over the entire tumor space was defined as D =
(A*Dpore small + B*Dpore large) where Dpore smal and Dpore large are the diffusivities in the small and
large pores respectively, and A and B are the relative amounts of diffusion that take place
through each pore size (A + B = 1).
Using the same self-consistent two pore representation of the tumor interstitial space, the
available volume fraction can be described using the equation:
- Vi(A*p pore _small +B*9pore _l arge ) (3.2)
where Vi is the interstitial fluid volume fraction, A and B are the ratios of small and large pores,
and Pporesmall and 9pore large are the partition coefficients of molecules in each pore size defined as
9 = (1 - ) 2 for k < 1, and 9 = 0 for k > 1 (13). From small molecule tracer studies, Vi was
approximated as 0.5 (7). Since both the interstitial diffusivity and void fraction are described by
the same model of the interstitial space, data sets describing each parameter (Appendix B. 1, B.2)
were simultaneously fit to the respective equations to determine values for Rporesman, Rporeiarge,
A, and B.
The effect of molecular radius on vascular permeability was similarly modeled using a
two-pore representation of the tumor capillary wall. Transport was assumed to be primarily
diffusive in nature due to high interstitial fluid pressure in tumors (14), such that permeability
across a pore (cm 2/s) can be modeled as:
Ppore = Dfree *(D ore Dfe (33)
where Dfree, (Dpore/Dfree), and p are defined as above (13). Total permeability through small and
large pores was defined as P = Acap*Pcapporesmall + Bcap*Pcap_porelarge where Acap and Beap are the
fractional capillary pore areas per unit membrane thickness (cm 1) for small and large pores
respectively. As above, the model was fit to experimentally determined P values (Appendix B.3)
to estimate Acap, Bcap, Rcap_poresmanl, and Rcap_pore large. While these parameters are similar to those
used to describe D and s, here they are describing pores in the capillary wall versus pores in the
interstitial space of the tumor.
Due to the various routes and complexities inherent in plasma clearance, there are no
simple structural models to describe the size dependency of the clearance term kciear. Instead a
largely empirical model was utilized for the renal and non-renal routes of clearance. For renal
clearance, macromolecular filtration can be described as C1R = GFR * ®, where ClR is the renal
clearance in mL/hr, GFR is the rate of fluid filtration across the glomerular wall estimated at 10
mL/hr in female mice (15), and E is the macromolecular sieving coefficient. The sieving
coefficient depends on molecular size and can be described as (16):
-= _ IK 0 n """ -aPe (3.4)1-e- + (Kconve-
where (D is the equilibrium partition coefficient, a is a correction term for the geometry of the
glomerular slits approximately equal to 2 for baseline glomeruli, KO, is the solute hindrance
factor for convection, and Pe is the Pclet number defined as:
Pe=(QKn,)vL (3.5)
(QKdff )Dfree
In this description, v is the fluid velocity vector estimated at 0.001 cm/s, L is the membrane
thickness approximated at 100 nm in mice (17), Dfree is the diffusivity in solution discussed
above, and Kiff is the diffusive hindrance factor. Since there are limited mechanistic models for
the effect of size on the hindrance factors Koon, and Kdiff, they, along with the partition
coefficient, are defined using empirical terms as reported previously (18):
DKdff =exp(-aRmoi) (3.6)
(DKcon, exp(-#iRog ) (3.7)
where Rmoi is the molecular radius of the targeting agent and a and p are empirical constants fit
to the data (units nm'). Non-renal clearance was incorporated to account for plasma loss of
molecules above the cutoff size for glomerular filtration. With several route of clearance and no
structural models a fully empirical description was used with the form:
ClNR = ClNR,o - rmol 3.8)
(rmol +)
where Clo is the non-renal clearance for small molecule tracers (mL/hr), and 6 (mL/hr) and y
(nm) are empirical constants fit to the data. While this equation has no physiological
significance, it is consistent with experimental observations of decreasing non-renal clearance
with increasing molecular size down to a constant level for large molecules (19). CI.No was
arbitrarily set to 2 mL/hr to account for the dominance of renal clearance in the size range of
small peptides.
The single exponential plasma clearance term kcear (units hr-1) was then defined as:
kc CiR +ClNR (
Vplasma
where Vpiasma is the plasma volume estimated in mice as 2 mL (20). For predictions of tumor
uptake in human patients, the plasma volume was increased to 3 L. This equation was fit to
experimental measurements of kolear for molecules of various sizes (Appendix B.4) to determine
the constants a, [, 6, and y. Although a biexponential description of plasma clearance is more
physiologically accurate, the single exponential term is a reasonable approximation that allows
us to better describe the broad features of size dependent clearance over the entire continuum of
molecular radii using a single parameter.
Tumor uptake of targeting molecules was simulated using a mechanistic compartmental
model of antibody uptake in tumors' (Figure 3.1), in which tumor concentration following a sub-
saturating bolus iv injection can be described as:
[Ab] = 2 PRcap [Ab] piasma,O (e"kcat -
e t
tmor R 2og (Q - ketear )RKrogh (3.10)
Thurber GM, Wittrup KD. A mechanistic compartmental model for antibody uptake in tumors. Submitted
cR + d(3.11)
where [Ab]piasma,o is the initial plasma concentration of the targeting agent (%ID/mL), t is the
time, [Ag] is the target antigen concentration (M), ke is the rate of endocytic clearance (sec-1), Kd
is the targeting molecule's affinity for the antigen (M), Reap is the capillary radius (jim), and
RKrogh is the average radius of tissue surrounding each blood vessel (pim). P, s, and kciear
represent permeability, available volume fraction, and plasma clearance rate, respectively, with
values for each sized molecule taken from the fits described above. The diffusivity term (D)
does not appear in the above equations as Thurber et al. demonstrated in the model derivation
that antibody uptake from the tumor surface is negligible relative to vascular uptake for most
experimentally or clinically relevant tumor types and sizes, and that the permeability term is the
rate limiting step in vascular uptake. The diffusivity term is still included in the methods for
fitting interstitial pore size, however, as it provides a check for self-consistency with the size-
dependent trends in available volume fraction. Size-independent parameter values were
estimated from the literature or were varied as described in each simulation. For figures plotted
as a function of effective molecular weight, estimates were made from radius using the
relationship MW = 1.32*Rmoi 3 (fit from data in reference (21)).
Using the above model, the time of peak tumor uptake following bolus injection can be
defined as:
In kciear
top = (kciear - (3.12)
where Q is defined in Equation 3.11.
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Figure 3.1 - Schematic depiction of the compartmental model used to simulate tumor uptake.
Parameters are defined in the text.
3.3 - Results
3.3.1 - Relationship of molecular size to transport parameters
The molecular size of a tumor targeting agent influences four parameters involved in
tumor uptake: plasma clearance (kciear), capillary permeability (P), interstitial diffusivity (D), and
available volume fraction in the tumor (s). Values of these parameters for molecules of different
sizes were collected from experimental studies reported in the literature (Appendix B) and used
to fit models of the capillary wall, tumor interstitial space, and renal and non-renal routes of
plasma clearance. While these models may not fully represent the physiological phenomena
behind each parameter, they provide a reasonable framework for describing experimental trends
in these parameters over the range of targeting agent sizes.
The interstitial diffusivity and available volume fraction data sets are best described by a
two-pore model of the tumor interstitial space with pore radii of 13.8 nm and 1 pm at a ratio of 9
to 1 (Figure 3.2A,B). The small pore size is consistent with previous descriptions of size
dependent transport in the tumor interstitial space (11), while the large pores are necessary to
account for the observed diffusion of 2 MDa dextran and liposomes. Similarly, the relationship
between molecular radius and transcapillary permeability was well fit by a two-pore model of the
capillary wall with 4.5 nm and 500 nm radius pores with fractional area to thickness ratios of
17.6 cm' and 0.65 cm~1, respectively (Figure 3.2C). These values are again physiologically
reasonable as -5 nm pores are typical of healthy vasculature (13), and larger pores with 500 nm
radii have been observed in leaky tumor vessels due to overexpression of VEGF and other
hyperpermeability factors (21).
The effect of size on plasma clearance is difficult to model as it is influenced by both
renal and non-renal routes of clearance. As such, a largely empirical model of plasma clearance
was derived with resulting parameters of a = 1.6 nm', p = 0.95 nm", 8 = 1.94 mL/hr, and y =
0.20 nm (Figure 3.2D). While these parameters have no physiological significance, they produce
a fit that closely resembles the trend in the data and is similar to previous empirical descriptions
of size dependent clearance (22). Plasma clearance data for IgGs are displayed separately and
not included in the fit as the Fc domain significantly reduces clearance through interactions with
endothelial FcRn receptors (23).
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Figure 3.2 - Size dependent transport parameters. A,B: Relationship between molecular radius
and effective diffusivity (D) and available volume fraction (s) in the tumor. Data points were
simultaneously fit to a two pore model of the tumor interstitial space. C: Relationship between
molecular radius and effective molecular permeability across the tumor vasculature (P). Data
points were fit to a two pore model of the capillary wall. D: Relationship between molecular
radius and plasma clearance rate (kciear). Data points were fit to an empirical model of renal and
non-renal clearance. IgG clearance is denoted by an open circle and was not included in the fit.
All data fitting was performed using a non-linear least squares method. Data points were
collected from experimental results reported in the literature and include measurements of
proteins (circles), dextran and PEG polymers (squares), small molecule tracers (diamonds), and
liposomes (triangles). Additional descriptions of the experimental data are presented in
Appendix B.
3.3.2 - Predicted maximum tumor uptake
A previously described compartmental model of tumor uptake was used to predict the
peak tumor concentration achieved for radiolabeled HER2 targeting molecules of various sizes
following a bolus iv injection. Values for P, s, and kcle& were determined for each size using the
relationships derived above. Size-independent model parameters were estimated for a well-
vascularized HER2 expressing xenograft model from values in the literature and are presented in
Table 3.1. While molecules bound to HER2 typically undergo net cellular internalization with a
half time of -6-8 hours ( ref (24) and unpublished results) endocytic clearance in the context of
measured total tumor uptake of radiolabel depends also on the rate at which degraded label is
cleared from the cell. Therefore we simulated two different radiolabels, faster-clearing 1251 and
residualizing 99mTc (25).
Table 3.1 Size-independent parameters
Parameter Value Reference
[Ab]piasmao 50 %ID/mL Assuming 2 mL plasma volume in mice
[Ag] 150 nM (13)
Reap 8 pm (46)
RKrogh 50-100 pm (47,48)
k, (1251) 1.6E-5 sec~ (49)
ke (99mTc) 4.8E-6 sec~1  (28,50)
The simulations predict a complex relationship between peak tumor accumulation and
size (Figure 3.3A). In general, predicted tumor uptake is highest for small targeting agents and
decreases with increasing molecular radius due to the size-dependent decrease in tumor capillary
permeability and available volume fraction reflected in Figures 3.2B and 3.2C. However, this
trend briefly reverses in the size range typical of proteins producing a local minimum for tumor
uptake at a radius of-2.8 nm and a local maximum at ~6.5 nm. The existence of the minimum
and maximum in this curve can be attributed primarily to the sigmoid dependence of renal
clearance on size (Figure 3.2D). Molecules in this size range start to become larger than the
kidney filtration cutoff leading to sustained circulation in the plasma which provides increased
chances for extravasation into the tumor. Although capillary permeability and available volume
fraction are still decreasing in this size range, the decrease in systemic clearance is greater,
producing a net increase in tumor uptake. IgGs are predicted to achieve significantly higher
tumor uptake than other molecules of equivalent size as a result of their slower plasma clearance
due to size-independent FcRn-mediated salvage. The use of residualizing 99mTc is predicted to
increase peak tumor uptake relative to 1251 labeled molecules when used with large molecules.
Model predictions for 99mTc labeled targeting agents in the size range typical of proteins
(2-500 kDa) were compared to data from experimental HER2 targeting studies in the literature
(Figure 3.3B). Each data point represents the highest tumor concentration achieved by a given
targeting agent over an experimental time course (Appendix B.5). Since the RKogh value for
intercapillary spacing is the least well-characterized parameter in the model and depends on the
extent of vascularization and necrosis within the tumor, simulations were performed for a range
of values between 50 and 100 pm. While the computational predictions differ quantitatively
from the experimental uptake for several molecules in this size range, the overall trends are
consistent. In both the simulations and experimental precedents, intermediate sized proteins
(~25 kDa) have the lowest tumor uptake while higher levels of targeting are achieved by smaller
or larger agents. Higher predicted IgG uptake in the range of 30-40 %ID/g is also consistent
with experimental precedents (Appendix B.5).
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Figure 3.3 - Predicted effect of molecular size on maximum tumor uptake. A: Predicted peak
tumor concentrations of HER2 binding molecules (Kd = 1 nM) labeled with 125I (solid line) or
residualizing 99mTc (dashed line). IgG uptake was simulated independently (open circle - 1251
solid circle - 99mTc) and is predicted to be higher due to FcRn mediated reduction in plasma
clearance. The vertical grey lines highlight the size range typical of protein therapeutics that is
further analyzed on the right. B: Comparison to experimental data. Peak uptake simulations
were performed as above and plotted as a function of effective molecular weight. The predicted
uptake trends for Rxiogi= 50 pm and R,<ogh = 100 jim form the upper and lower bounds
respectively of the shaded grey area. Data points were collected from HER2 targeting
experiments in the literature including 99mTc, "In, and "Cu labeled molecules of various sizes.
References and additional details for each experimental data point are presented in Appendix
B.5. The units of radius and effective MW used in the left and right panels, respectively, can be
related using the relationship MW = 1.32*Rmol3 (for example 7 kDa affibodies, 27 kDa scFvs, 50
kDa Fabs, and 150 kDa IgGs have radii of 1.74 nm, 2.74 nm, 3.47 nm, and 4.86 nm,
respectively.)
3.3.3 - Time dependence of tumor uptake
The time of peak tumor uptake and length of tumor retention also have important
implications for imaging and therapy. Therefore, full time course simulations were performed
for 12sI or 99mTc labeled HER2 targeting molecules (K-d = 1 nM) ranging in size from 2-1000
kDa. As reported above, peak tumor levels are similar for proteins at the small and large ends of
this size range with a local uptake minimum in between (Figure 3.4A,B). The time at which
peak uptake occurs, however, differs significantly as small macromolecules reach their
maximum tumor level within minutes, while uptake of larger molecules occurs on the time scale
of hours to days (Figure 3.4C). Targeting agents labeled with residualizing 99mTc are predicted
to achieve peak tumor uptake at later time points and display significantly greater tumor
retention than those labeled with 1251 as expected given their differences in cellular clearance.
The predictions in Figures 3.4A-C are valid only for molecules lacking Fc domains or other
active trafficking as FcRn mediated salvage increases the time until peak tumor uptake by
increasing serum persistence.
Computational predictions were compared to published biodistribution time courses for
anti-HER2 proteins labeled with 99mTc (Figure 3.5) (26-29). In order to more directly compare
the time-dependency of the predicted uptake, the magnitude of uptake (%ID/g) was adjusted in
each case by fitting the Rxiog value to the experimental data. For high affinity targeting
molecules (Id << [Ag]) as is the case here, the Rogh term impacts the height of the curve but
has no influence on the shape or time of peak uptake. In all cases, the computationally predicted
time course of tumor loading and retention matches the experimental results well. Affibodies
and scFvs achieve peak uptake within the first few hours while larger tetramer and IgG
molecules achieve tumor uptake more slowly. IgGs in particular have very slow tumor
accumulation with peak uptake after days due to the slow rate of plasma clearance driven by
FcRn mediated salvage.
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Figure 3.4 - Predicted effect of molecular size on time course of tumor uptake. Tumor uptake
over time was simulated for 125I (A) or 99mTc (B) labeled non-Fc domain containing HER2
binding molecules (Kd = 1 nM) ranging in size from 2-1000 kDa. C: Effect of molecular size on
the time of maximum tumor uptake for 125I (solid line) or 99"Tc (dashed line) labeled molecules.
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Figure 3.5 - Comparison to experimental data. Tumor uptake simulations were performed for
affibodies (MW = 7 kDa), scFvs (27 kDa), tetrabodies (130 kDa), and IgGs (150 kDa) and
compared to experimentally measured time courses for 9 9mTc labeled HER2 targeting
molecules (26-29). RKrogh values were fit to the experimental data for each molecule using the
least squares method with results of 57, 80, 101, and 84 Im for the affibody, scFv, tetrabody, and
IgG data sets respectively. These values are all in a physiologically reasonable range.
3.3.4 - Affinity dependence of tumor uptake
Experimental and theoretical analyses suggest that increasing the affinity of a targeting
molecule for its antigen will increase tumor localization up to a point at which tumor levels
plateau (9,30). However, the precise affinity at which maximum tumor uptake is achieved
depends on the targeting molecule's size. To examine this relationship in more detail,
calculations were performed to predict the tumor uptake at 24 hours for macromolecules varying
in both molecular size and affinity. For all sizes in the range of 1-1000 kDa, the expected
improvement in tumor uptake with increasing affinity was observed up to a plateau at high
affinities (Figure 3.6A). The threshold affinity of this plateau was size dependent, however, as
smaller proteins require tighter binding on the order of 10~10 to 10-8 M Kd values to maintain
significant tumor uptake, while large molecules are able to achieve similar uptake levels at much
lower affinities in the 10-8 to 10-6 M Kd range (Figure 3.6A, B). IgGs, for instance, require only a
6 x 10-7 M affinity to achieve 50% of their peak tumor uptake at 24 hours. The differences in
affinity dependence are due to the fact that small, unbound molecules are cleared rapidly from
the tumor through vascular intravasation due to their high capillary permeability. As such, small
proteins must be anchored to the antigen through high affinity interactions to be retained. In
contrast, large, unbound molecules intravasate slowly such that moderate affinity molecules are
able to rebind repeatedly and remain in the tumor.
Computational predictions were compared to experimentally reported tumor uptake data
for anti-HER2 scFvs ranging in affinity from 15 pM to 320 nM (30). The model accurately
predicts the experimental trend in which the three highest affinity scFvs have similar uptake
while lower tumor uptake levels are observed for the 16 nM and 320 nM Kd molecules (Figure
3.6C).
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Figure 3.6 - Binding and affinity dependence. A: Predicted tumor uptake at 24 hours for "mTc
labeled HER2 targeting molecules varying in both size and affinity for the target antigen. B:
Affinity necessary to achieve 10% (small dashes), 50% (large dashes), or 90% (solid line) of the
maximum tumor uptake at 24 hours as a function of molecular size. C: Comparison to
experimental data. The predicted 24 hour tumor concentration for HER2 targeting scFvs (MW =
27 kDa) of various affinities were compared to experimental uptake measurements for affinity
variants of the C6.5 scFv (30). Model predictions and experimental data are normalized by their
respective uptake values for the highest affinity case.
3.3.5 - Non-binding mediated uptake: size dependence of the enhanced permeability and
retention (EPR) effect
Experimental studies have suggested that significant tumor accumulation of large
macromolecules may occur even in the absence of tumor-specific binding due to the EPR
effect (31). We therefore calculated the uptake of untargeted macromolecules relative to the
tumor levels of size-matched molecules that bind the target antigen with a 1 nM Kd (Figure
3.7A). The simulations demonstrate that at early time points uptake is similar for non-targeted
.... .. ................... .  .   .. 
and targeted molecules for all but the smallest peptides. Following this initial uptake phase,
unbound molecules are cleared rapidly from the tumor while bound molecules are retained,
producing a high level of specificity of targeting at later time points for molecules in the size
range of most proteins (radius < 10 nm). In contrast, larger molecules in the size range of
liposomes (~50 nm) are predicted to have similar tumor levels of targeted and non-targeted
molecules even at later time points, as uptake is dominated by EPR effects. This situation arises
as the slow clearance of large, unbound molecules by vascular intravasation occurs at the same
rate as clearance of antigen-bound molecules by cellular internalization and degradation. These
model predictions are consistent with experimentally measured values of tumor uptake
specificity (Figure 3.7B).
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Figure 3.7 - EPR mediated non-specific uptake. A: Predicted tumor concentrations of non-
targeted molecules (Kd = 1 M) ranging in radii from 0.5-60 nm were calculated for various times
and normalized by the predicted uptake of size matched antigen binding molecules with a Kd of 1
nM (untargeted to targeted uptake ratio). A value of 0 represents fully binding mediated tumor
retention, while a value of 1 represents equivalent uptake of targeted and non-targeted molecules.
Ryrogh = 100 pm. B: Comparison of non-specific uptake predictions to experimental
measurements of specificity. The simulations were performed as described in Figure 4D of the
main text using HER2 parameters and size-dependent values for affibodies (Rmoi = 1.74 nm),
IgGs (Rmoi = 4.85 nm), and liposomes (Rmoi = 50 nm). Experimental values of specific and non-
specific uptake were taken from the literature and reported as a ratio. Non-specific affibody
uptake was measured by pre-blocking antigen with an excess of unlabeled affibody and reported
in references (28,32,33). Non-specific IgG uptake was measured using a non-HER2 specific
control antibody and reported in reference (34). Non-specific liposome uptake was measured
with a particle lacking targeting antibodies and reported in reference (35).
3.3.6 - Predicted uptake in human tumors
While comparisons to mouse xenograft studies are a useful validation for model
predictions of size dependent trends, the true utility of a model depends on its ability to predict
tumor uptake in human patients. Therefore, simulations were performed for tumor uptake of
targeting agents of various sizes in human subjects and compared to clinical data for uptake of
anti-carcinoembryonic antigen (CEA) scFv, F(ab') 2, DFM, and IgG molecules labeled with
"1 (36). [Ab]pasmao was reduced from 50 %ID/mL to 0.033 %ID/mL due to the increase in
plasma volume from 2 mL to 3 L, and the [Ag] and ke values were changed to 300 nM and 9.6E-
6 sec~1 to reflect the different expression and trafficking properties of CEA (37). All other
parameter values were left the same as used in the mouse studies as they should be relatively
independent of animal species or body weight in their stated form and few measured values are
available for human patients. The predicted max tumor level for molecules ranging in size from
peptides to liposomes is presented in Figure 3.8A. The size-dependent trends are identical to
those observed in the mouse simulations, while the absolute values are significantly reduced due
to the increased plasma volume. The predicted uptake levels in the size range of proteins match
closely with the clinically measured tumor concentrations (Figure 3.8B).
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Figure 3.8 - Predicted tumor uptake in humans. Simulations were performed as described in
Figure 2 except with Vpiasma = 3L, and [Ag] and ke adjusted for targeting CEA. A: Predicted
peak tumor concentrations in humans of CEA binding molecules (Kd = 1 nM) labeled with 1251
IgG uptake was simulated independently and denoted by the solid circle. B: Comparison to
clinical data. Peak uptake simulations were performed as above and plotted as a function of
effective molecular weight in the size range typical of proteins (2-500 kDa). The predicted
uptake trends for Ro0gh = 50 ptm and R1 oh = 100 ptm form the upper and lower bounds
respectively of the shaded grey area. The data points represent clinically measured tumor
concentrations for scFv, F(ab') 2, DFM, and IgG molecules targeting CEA expressing tumors in
humans (36).
3.4 - Discussion
The increased development of novel tumor binding agents for applications in cancer
therapy and imaging has raised the question of how size differences among these molecules
impact their targeting properties. Here we incorporate derived relationships between molecular
radius and the transport parameters permeability, available volume, and plasma clearance into a
compartmental model of tumor uptake to quantitatively assess the effect of molecular size on the
magnitude and specificity of tumor localization. Despite the simplicity of the model, we are able
to accurately predict several experimental trends for HER2 targeting molecules in mice and CEA
targeting molecules in humans, suggesting that size and affmity alone can largely account for the
targeting properties of most macromolecules. The modeling framework presented here can also
be applied to other tumor types and antigens by simply altering the relevant parameters, which
can be independently measured.
While several groups have experimentally or computationally compared tumor uptake for
small sets of different sized molecules (27,38,39), here we compare molecules across a broad
continuum of molecular radii uncovering complex trends of size dependency. In particular, the
model predicts that in the size range of most protein agents, there is a local uptake minimum at
~25 kDa while larger and smaller agents achieve higher tumor levels. This prediction is
consistent with experimental measurements of HER2 targeting molecules and suggests that small
proteins such as affibodies and DARPins, along with larger molecules including multimers and
PEGylated proteins should be superior targeting agents compared to scFvs. For large molecules,
uptake can be further increased by incorporation of Fc or albumin binding domains to actively
reduce plasma clearance (23,40).
Although small and large proteins are predicted to have similar peak tumor levels, they
differ significantly in the time and affinity dependence of uptake. Small proteins achieve high
tumor levels rapidly but require high affinity to be retained, as unbound molecules clear from the
tumor rapidly. The rapid uptake of small proteins combined with their efficient clearance from
the plasma and normal tissues may make them ideally suited for imaging applications (3). In
contrast, large molecules can achieve high uptake at comparatively low affinities but accumulate
in the tumor on a much slower time scale. These molecules may be best suited for multi-step
pretargeting strategies in which the slow clearance from the plasma can be augmented by
clearing agents (41).
Outside the size range of typical protein agents, the model predicts very high tumor
uptake for small, hydrophilic, high affinity peptides (low nM or pM Kj). Unfortunately,
identifying small peptides that bind tightly is difficult. Most linear or cyclic peptides selected for
de novo binding interactions have monovalent affinities on the order of high nM to pM
Kd (42,43). The formation of multivalent peptide agents or inclusion of synthetic peptidomimetic
domains can contribute to higher affinity (43-45), but these agents may have additional
pharmacokinetic problems including plama protein binding, biliary clearance, and kidney
localization (46). There are, however, some small natural ligands that bind tightly to tumor
receptors and achieve high tumor accumulation as predicted by the model. Somatostatin
antagonists and glucagon-like peptide analogues have been shown to achieve tumor levels of 61
and 287% ID/g, respectively, in mouse tumor models (47,48). While these high tumor levels
may be partially attributable to differences among the tumor models or target antigens, they
provide enticing precedents that may motivate future development of targeting agents in this size
range.
At the other end of the size spectrum, the model predicts lower tumor uptake levels on
the order of 1-2 %ID/g for liposomes and other large targeting agents. There are several caveats
for making general predictions about liposome and nanoparticle uptake including molecular radii
close to the capillary cut-off and greater variation in molecular geometry and chemical structure
relative to proteins. Nevertheless, the model predictions are consistent with experimentally
measured uptake values of 1-8 %ID/g for a majority of liposomes and nanoparticles (35,49,50).
One of the more intriguing predictions from the model is that for molecules beyond a
certain size there is little to no increase in tumor uptake from antigen targeting. The precise size
at which this targeting independent uptake dominates depends on several parameters, but is
generally predicted to occur in the -50 nm size range typical of liposomes and nanoparticles.
These predictions are consistent with several experimental reports of insignificant differences in
tumor levels of liposomes and nanoparticles with or without targeting ligands (35,49). In
contrast, antigen specific targeting may be observed with smaller particles, in tumors with high
vascular permeability, or by targeting antigens on the luminal side of the tumor vasculature. For
vascular targeting agents in particular, the entire analysis of extravasation and diffusion
presented here is irrelevant. It is also important to note that antigen targeting may still improve
the therapeutic efficacy of liposomes and nanoparticles even without altering the total tumor
concentration by increasing the amount of drug internalized by cells within the tumor (35).
Given the large number of parameters used in the model and the inherent variability in
these parameter values due to tumor heterogeneity and experimental error, it is inevitable that
there will be some variation or error in the tumor uptake predictions presented here for specific
molecules in a given tumor. We believe, however, that the overall trends predicted by the model
including predominance of EPR in liposome targeting, and the greater importance of high
affinity for small binding molecules should be relatively consistent as they are well supported by
published experimental evidence. Better understanding of these trends through the modeling
framework presented here should aid in the future design of targeting agents with improved
uptake and specificity.
Notes - This chapter was reproduced in large part from Schmidt MM, Wittrup KD. A modeling
analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer
Ther. 8:2861-71, 2009.
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3.5 - Parameter definitions
Diffusion coefficient in tumor (cm 2/s)
Tumor capillary permeability (cm/s)
Available volume fraction in the tumor
Single exponential plasma clearance rate (hr 1)
Capillary radius (pm)
Radius of tissue surrounding capillary (pm)
Initial plasma antibody concentration (%ID/mL)
Average concentration of total antibody (bound + free) in tumor (%ID/g)
Antigen concentration in tumor (M)
Antibody dissociation constant (M)= ko/kn
Internalization/degradation rate of bound antibody (sec-)
Diffusion coefficient in solution (cm 2/s)
Diffusion coefficient in cylindrical pore (cm 2/s)
Hydrodynamic radius of the targeting molecule (nm)
Radius of the pore (nm)
Ratio of molecular radius to pore radius
Interstitial fluid volume fraction in tumor
Partition coefficient in pore
Relative amounts of diffusion through small and large pores, respectively
Fractional capillary pore areas per unit membrane thickness through small
and large pores, respectively (cm-)
Renal clearance (mL/hr)
Glomerular filtration rate (mL/hr)
Macromolecular sieving coefficient
Equilibrium partition coefficient at glomerular wall
Correction term for geometry of glomerular slits
Solute hindrance factor for convection
Diffusive hindrance factor
Peclet number, ratio of convection to diffusion
Fluid velocity vector (cm/s)
Membrane thickness (nm)
Empirical constants for describing kidney filtration (nm')
Non-renal clearance (mL/hr)
Empirical constants for non-renal clearance (units mL/hr and nm, respectively)
Plasma volume (mL)
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Chapter 4 - Tumor targeting properties of monovalent ds(Fv)-Fc antibody fragments
4.1 - Introduction
In Chapter 3, a computational model was developed that describes the effects of
molecular size and binding affinity on tumor targeting. The model predicts a complex trend in
which two regions of the size parameter space achieve high levels of tumor uptake (Figure 3.3).
First, small peptides approximately 1-10 kDa in size accumulate efficiently in the tumor due to
rapid capillary extravasation, but require high affinity binding interactions to be retained.
Second, proteins approximately 100-300 kDa in size achieve high uptake as they are large
enough to escape rapid kidney filtration, while small enough to have reasonable extravasation
rates into the tumor. Notably, 150 kDa IgGs have significantly higher uptake than other
molecules in this range due to their slow plasma clearance mediated by FcRn recycling (1). A
similar effect has been observed for antibodies directly or indirectly fused to albumin (2,3),
which also has extended serum persistence due to FcRn binding (4,5).
One area of the size parameter space that has not been fully explored is smaller fragments
of the IgG that retain full FcRn mediated salvage activity. As discussed in Chapter 3, most non-
Fc containing antibody fragments suffer from rapid kidney filtration that offsets the benefit of
faster extravasation and leads to lower total tumor uptake. Renal filtration may be lower for Fc
conjugates, however, as there is evidence that the Fc domain can mediate reabsorption of filtered
proteins in the kidneys. FcRn receptors are expressed in both podocytes and renal proximal
tubular epithelial cells of the kidney, and are believed to contribute to transcytosis of filtered IgG
and albumin molecules from the proximal tubules back into circulation (6-8). Perhaps due to
this FcRn mediated reabsorption, papain cleaved Fc domains (MW -50 kDa) have plasma
clearance properties similar to the full IgG (9). If the Fe domain is in fact able to limit kidney
filtration and extend serum persistence of antibody fragments, then the greater permeability, void
fraction, and diffusivity of these smaller agents may lead to high tumor uptake. To test these
possibilities, we engineered a 79 kDa, monovalent ds(Fv)-Fc anti-CEA antibody fragment and
tested its targeting properties in mice relative to the full length IgG.
The IgG format consists of two 50 kDa heavy chains and two 25 kDa light chains (Figure
4.1). The pairing of the heavy and light chains forms two binding arms, each consisting of a
variable domain (Fv) and constant domain (CHi), connected to a homodimeric Fc domain (CH2-
CH3) through a disulfide hinge. The variable domain, comprised of a FvH and FvL heterodimer,
forms the antigen binding site, while the CHI domain provides stability and modularity.
Stability can alternatively be introduced by a disulfide bond or peptide linker between the FvH
and FvL (10,11). The Fc domain is the site of binding to the FcRn salvage receptor, as well as
Fc receptors involved in antibody dependent cellular cytotoxicity (ADCC) and other effector
functions (9,12).
To create the 79 kDa ds(Fv)-Fc format, the CH1 domain was removed from the heavy
and light chains and replaced with a disulfide bond between the variable domain framework
regions to form ds(Fv)L and ds(Fv)H-Fc subunits. Next, a truncated variant of the heavy chain
was constructed consisting only of the hinge and Fc domain. When co-secreted with the
modified light and heavy chains, the Fc fragment pairs with the shortened ds(Fv)H-Fc to form an
Fe heterodimer connected to a single antigen binding arm (Figure 4.1). The final product is a
disulfide stabilized trimer consisting of a 13 kDa His-tagged ds(Fv)L domain, a 39 kDa ds(Fv)H-
Fc domain, and 27 kDa FLAG-tagged Hinge-Fc domain (Figure 4.1). Here we demonstrate that
anti-CEA ds(Fv)-Fcs can be secreted and purified from Hek cells in high yields, bind to CEA
expressing cells in vitro with predicted monovalent affinities, and target CEA expressing tumors
in vivo in a comparable manner to full length IgGs.
4.2 - Methods
Plasmid construction
gWiz vectors (Genlantis) encoding the heavy and light chains of anti-CEA IgG clones shMFE
and sm3E were obtained from Kelly Davis. The heavy chain sequence for the two clones is
identical, while the light chains differ at three amino acids (13). Plasmids encoding the
ds(shMFE)-Fc and ds(sm3E)-Fc proteins were constructed using standard molecular biology
techniques. Disulfide stabilizing cysteine residues were inserted into each variable domain as
described previously (14). Next, a BamHI restriction site downstream of the open reading frame
was removed from both plasmids by Quikchange mutagenesis using primers 4.1 and 4.2 (see
Table 4.1 for oligonucleotide sequences). For the two ds(Fv)L vectors, a N-terminal NheI site
was added to the light chain plasmid by Quikchange mutagenesis with plasmids 4.3 and 4.4. The
light chain variable domains of shMFE and sm3E were PCR amplified using oligos 4.5 and 4.6
and ligated into the modified light chain backbone digested with NheI and SalI. PCR
amplification with oligo 4.6 also added a c-terminal His tag to the ds(Fv)L constructs. For the
ds(shMFE/sm3E)H-Fc construct, the heavy chain variable domain was PCR amplified with
oligos 4.7 and 4.8, then subcloned back into the heavy chain backbone cut with MluI and NheI.
This ligation removed an NheI site between the Fv and CH1 domains and added a new NheI site
at the N-terminus. The NheI modified heavy chain was then Quikchanged with oligos 4.9 and
4.10 to remove the CH1 domain. For the truncated Fc construct, the heavy chain leader
sequence was replaced by an IL-2 leader sequence by annealing oligos 4.11 and 4.12 and ligating
the insert DNA into the NheI modified heavy chain vector cut with PstI and NheI. The Fc
portion of the heavy chain vector, including the hinge, was then PCR amplified using primers
4.13 and 4.14 and ligated into the IL-2 leader sequence backbone digested with NheI and SalI.
Oligo 4.14 also introduced a c-terminal FLAG tag into the vector. All mutations were confirmed
by sequencing. The final amino acid sequences of all constructs are presented in Appendix A.
Table 4.1 -Oligonucleotides for Chapter 4 constructs
Number Name Sequence
4.1 No Bam Ig Top GCTCTAGACCAGGCGCCTCGATGGAGATCACTTCTGGC
4.2 No Bam Ig Bott GCCAGAAGTGATCTCCATCGAGGCGCCTGGTCTAGAGC
4.3 LC Nhel QC Top CCAGGTGCACGATGTGCTAGCGAAAATGTGCTGACCCAATC
4.4 LC Nhel QC Bott GATTGGGTCAGCACATTTTCGCTAGCACATCGTGCACCTGG
4.5 LCL-NB-smK-N CGATGTGCTAGCGGTTCAGGATCCGAAAATGTGCTGACCCAATCTCCAAG
4.6 dsFv-cterm-saII TATAGTCGACCTATTAATGGTGATGATGGTGATGTGATCCTGCAGCAGCCTTGATTTCCAACTTCGTTCCAC
4.7 FabH MIu/Nhe ATAAACGCGTGCTAGCGGTTCAGGATCCCAAGTTAAACTGGAACAGTCC
4.8 E C AvrIl ATATCCTAGGGCTAGAGACAGTAACTAAGGTTCCTTGTCCC
4.9 FvFc-short-top GGAACCTTAGTTACTGTCTCTAGCGCAAGCGACAAAACTCACACATGCCCACCGTG
4.10 FvFc-short-bott CACGGTGGGCATGTGTGAGTTTTGTCGCTTGCGCTAGAGACAGTAACTAAGGTTCC
4.11 IL2 SP Top GATGTACAGAATGCAACTCCTGTCTTGTATAGCACTAAGTCTTGCACTTGTCACGAACTCGGGAGGTGGCG
CTAGCGCCACCTCCCGAGTTCGTGACAAGTGCAAGACTTAGTGCTATACAAGACAGGAGTTGCATTC
4.12 IL2 SPBott TGTACATCTGCA
4.13 Fc-Short-N TATAGCTAGCGACAAAACTCACACATGCCCACCG
4.14 CH3-FLAG-C TATAGTCGACCTATTACTTGTCATCGTCGTCCTTGTAGTCTGAACCTTACCCGGAGACAGGGAGAGGC
Protein production in Hek cells
Plasmids were transfected into DH5a cells and selected on LB + Kan plates. For each plasmid,
400-800 pg of DNA was purified using either 30-60 minipreps (Qiagen) or 1-4 maxipreps
(Invitrogen) according to manufacturer's instructions. Where necessary, the plasmid DNA was
concentrated to 0.5-1 pg/pL by ultrafiltration in a Microcon YM-3 device (Millipore) and sterile
filtered in a SpinX column (Corning). Hek cells were inoculated at a concentration of 2.5 x 105
cells/mL in 40 mL Freestyle 293 Expression Medium (Gibco) in a 125 mL flask at 37*C. After
two days, the cells were transferred to a 500 mL flask, and 120 mL of fresh media added. Two
days later, the cells were diluted with fresh media to 800 mL, split into a pair of 2 L rolling
bottles, and grown to a final concentration of 1-1.5 x 106 cells/mL. For transfections, either 500
ptL of each of the IgG plasmids (light and heavy chains) or 333 IL of each of the ds(Fv)-Fc
plasmids (ds(FV)L, ds(Fv)H-Fc, and Hinge-Fc) were mixed with 10 mL of OptiPRO SFM media
(Gibco). Simultaneously in a separate tube, 1 mL of sterile PEI (1 mg/mL) was mixed with 10
mL of OptiPRO SFM. After 15 minutes at room temperature, the two tubes were mixed and
incubated for an additional 15 minutes. Each transfection mixture was then added to one of the
Hek cell roller bottle cultures along with 80 mL of fresh Freestyle 293 media. After an 8 day
incubation on rollers at 370C, the cells were pelleted at 6000 RPM and the cleared supernatant
sterile filtered.
Protein purification
The secreted IgGs were purified by Protein-A affinity resin (Pierce) using the manufacturer's
instructions and 1 mL of resin. Proteins were eluted with 100 mM glycine-HCl, pH 3.5, and
neutralized with 1/10* volume 1 M TRIS, pH 8.0. For the ds(Fv)-Fc constructs, proteins were
first purified using Talon His-tag purification resin (Clontech) according to the manufacturer's
column protocol. Since this step purifies ds(Fv)2-Fc homodimers in addition to the desired
ds(Fv)-Fc species, an additional purification step using M2 anti-FLAG resin (Sigma-Aldrich)
was performed. The His elution fractions were directly run over the anti-FLAG resin 2-3 times,
and the bound protein eluted with 100 mM glycine-HCl, pH 3.5 as above. Purified proteins were
buffer exchanged into PBS by multiple rounds of dilution and concentration using 10 kDa
Amicon-ultra 15 ultrafiltration devices (Millipore). Protein size and purity was confirmed by
running samples on 4-12% Bis-Tris gels and staining with SimplyBlue SafeStain (Invitrogen).
In vitro binding
Kd values for the purified proteins were measured on fixed LS 1 74T cells. In brief, LS 1 74T cells
were trypsinized and fixed with Cytofix buffer (BD Biosciences) for 20 minutes at 4*C. 100,000
fixed cells were incubated at 37*C with unlabeled antibody at a range of concentrations in PBS +
0.1% BSA. At each concentration, a sufficient volume was used to maintain a 10 fold molar
excess of antibody over antigen. After 24 hours, cells were pelleted, washed with 1 mL cold
PBS-BSA, and labeled with 200 piL Protein A-488 diluted 1:200 in PBS-BSA for 30 minutes on
ice. The cells were then pelleted and run on an XL-coulter flow cytometer (Beckman Coulter) to
measure the average Alexa-488 fluorescence per cell. The cellular fluorescence of control cells
labeled with ProteinA-488 but no primary antibody was measured as non-specific secondary
signal and subtracted from the total fluorescence. The corrected fluorescence values were fit to
the equation MFU = Bmax ([Ab]/([Ab]+K 1 )) to determine the Kd.
Protein radiolabeling
800 pg of each protein was diluted to a concentration of 1 mg/mL in PBS, pH 7.4, and mixed
with 5 iL of 0.1 M ammonium acetate with 50 mM EDTA at room temperature for 30 minutes.
The samples were then diluted in 15 mL 0.1 M Hepes, pH 8.5, and reconcentrated back to -250
iL using a 10 kDa Amicon Ultra- 15 filter unit. The dilution and concentration steps were
repeated, and the final protein concentrations adjusted to 2 mg/mL in Hepes. SCN-bz-DTPA
(Macrocyclics) was dissolved in 100% ethanol at a concentration of 50 mg/mL and mixed
immediately with the protein solutions. A sufficient volume of SCN-bz-DTPA was used for a 20
fold molar ratio of SCN-bz-DTPA to IgG or 10 fold ratio of SCN-bz-DTPA to ds(Fv)-Fc. The
reactions were incubated overnight at 4*C. The samples were then diluted with 15 mL 0.1 M
ammonium acetate, pH 6.0, and reconcentrated to 250 ptL as before. The concentration and
dilution steps were repeated 5-7 times until there was no SCN-bz-DTPA remaining in the flow
through as measured by absorbance at 280 nm. Concentrated DTPA-labeled proteins were
incubated with ~1 mCi "'InC 3 (Cardinal Health) for 30 min at room temperature. The reaction
mixture was diluted with 500 iL saline and concentrated to approximately 50 ptL using Vivaspin
5000 MWCO spin columns (Sartorius Stedim Biotech). The dilution and concentration steps
were repeated twice, and the "'In labeled proteins sterile filtered. Greater than 98% of the
isotope was associated with the protein as assessed by TLC. The specific activities were 1.045
ptCi/ig for sm3E IgG, 1.195 ptCi/tg for ds(sm3E)-Fc, 1.08 ptCi/pg for shMFE IgG, and 1.39
p.Ci/tg for ds(shMFE)-Fc.
Mouse biodistribution
All animal handling was performed in accordance with Beth Israel Deaconess Medical Center
Animal Research Committee guidelines. Xenografts were established in 5-6 week-old male
NCR-nu/nu mice (Taconic Farms) by subcutaneous injection of 2-4 x 106 CEA-positive LS174T
cells into the left flank and 0.5-1 x 106 CEA-negative C6 cells into the right flank of each mouse.
After 8-10 days, tumors were 0.1-0.5 g in mass. 100-150 gCi of "'In-labeled protein was
injected retro-orbitally in 100 pL saline. To prevent rapid plasma clearance of the human IgG1
proteins in the nude mice as described previously (15), a bolus of 500 pg non-indium labeled,
non-specific human IgG was co-injected with the radiolabeled samples. Blood samples of 10-15
gL were collected from the tail vein at various times and counted on a model 1470 Wallac
Wizard (Perken Elmer) 10-detector gamma counter. Mice were euthanized by intraperitoneal
injection of pentobarbital followed by cervical dislocation. Organs and tumors were resected,
washed in PBS thrice, weighed, and counted as described above.
Immunofluorescent tumor microdistribution
Female NCr nude mice (Taconic), aged 6-8 weeks, were injected subcutaneously with 5 x 106
trypsinized LS 1 74T cells in the rear flank. The tumors were grown to a diameter of 0.7 - 1 cm,
at which time 100 ig of unlabeled antibody in 200 iL PBS was injected via the tail vein. The
mice were sacrificed 24 hours post-injection. Tumors were excised, embedded in Optimal
Cutting Temperature (OCT) media, and snap frozen in isopentane over liquid nitrogen. Frozen
tumors were cryosectioned by the MIT Histology facility at a 5 im thickness and stored at -80
*C until staining. When ready for staining, tissue slices were thawed, air dried for 30 minutes at
room temperature, fixed with Cytofix Buffer (BD Pharma) for 10 minutes, and air dried again.
The samples were then washed 3 times with PBS and blocked with 5% goat serum for one hour.
The blocked samples were incubated with rat anti-CD3 1 (BD Pharmingen) at a 1:100 dilution in
5% goat serum overnight at 40C. In the morning, the slides were washed in PBS, then incubated
with Alexa-488 labeled goat anti-human Fc IgG (Invitrogen) diluted 1:200, Alexa-555 labeled
goat anti-rat IgG (Invitrogen) diluted 1:200, and Alexa-647 labeled mouse anti-CEA IgG (non-
sm3E competitive clone M85151a, Fitzgerald Industries) at 20 nM in 0.1% tween-PBS for one
hour at room temperature. The samples were washed again in PBS, then mounted with
Vectashield including DAPI (Vector Labs) and imaged on a Deconvolution-based high-
resolution fluorescence microscope (DeltaVision) with a 1 Ox objective. Multiple image panels
were taken covering the entire tumor then stitched together into a single image.
Computational modeling
Tumor uptake time course simulations were performed as described in reference (16). Antibody
microdistribution around capillaries was predicted with numeric simulations (17). Values for A,
a, B, $, and K4 were taken from the experimental plasma clearance studies and binding titrations.
RKrogh was estimated from the histology slices as 50 pim. Values for P, D, and & were taken from
the size dependent trends described in (16). Non-size dependent parameters were taken from
literature descriptions of CEA xenografts as summarized in (16).
4.3 - Results
Mathematical modeling predicts that proteins with small size and slow plasma clearance should
achieve high levels of tumor uptake. Therefore, we constructed a 79 kDa, monovalent ds(Fv)-Fc
antibody fragment consisting of a single disulfide stabilized Fv domain genetically fused to a
heterodimeric Fc. We compare the targeting properties of this novel antibody fragment to the
full 150 kDa, bivalent IgG for both low affinity (shMFE, Kd = 8.5 nM) and high affinity (sm3E,
Kd = 30 pM) anti-CEA variable domains (13).
4.3.1 - Protein production
Each ds(Fv)-Fc molecule is a disulfide stabilized trimer consisting of a His-tagged
ds(Fv)L domain, an untagged ds(Fv)H-Fc domain, and a FLAG-tagged Hinge-Fc domain (Figure
4.1). Plasmids encoding each subunit were constructed for both the shMFE and sm3E variable
domains and transiently transfected into Hek cells for secretion. After 8 days of secretion,
proteins were purified using sequential His-tag and FLAG-tag affinity chromatography. Full
length IgG variants of shMFE and sm3E were also secreted in Hek cells and purified by Protein-
A chromatography.
The ds(Fv)-Fc proteins were purified at a final yield of ~5 mg/L compared to yields of
-10 mg/L for the IgGs. The roughly 50% lower yield of ds(Fv)-Fc molecules is due to the
formation of bivalent ds(Fv)2-Fc tetramers in which two ds(Fv)H-Fc subunits pair. These species
are present at approximately equal concentration with the desired ds(Fv)-Fc trimers after His-tag
chromatography, but are efficiently removed during FLAG-purification. The purified IgG and
ds(Fv)-Fc molecules match their expected sizes on SDS-PAGE gels and are highly pure (Figure
4.2).
Fv-+
4 ds(Fv)
Light chain
CH1 -
Heavy chain
Fc -+Fc Truncated Fc
(CH2-CH3) CH2-CH3) Disulfide bond
IgG ds(Fv)-Fc ** His, FLAG tag
(145 kDa) (79 kDa)
Figure 4.1 - Domain structures of IgG and ds(Fv)-Fc antibodies. In the ds(Fv)-Fc molecule, the
CH1 domain is removed and replaced with an interdomain disulfide bond between variable
domains. A variant of the Fc domain truncated above the hinge pairs with the ds(Fv)H-Fc
subunit to form a heterodimeric Fc domain fused to a single binding arm
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Figure 4.2 - SDS-PAGE gel electrophoresis of purified proteins. Samples were run on a 4-12%
Bis-Tris gel and stained with SimplyBlue SafeStain. As expected, the IgG molecules run at a
significantly larger molecular weight than the ds(Fv)-Fc fragments.
4.3.2 - Cell-surface binding titrations
Binding affmities were assessed by K titrations on fixed CEA-expressing LS174T cells.
The monovalent ds(sm3E)-Fc and ds(shMFE)-Fc molecules bind with Kd values of 22.7 pM and
5.0 nM, respectively (Figure 4.3). These affinities are closely in line with previously measured
dissociation constants for monovalent ds(sm3E) and ds(shMFE) scFvs produced in yeast (14).
As expected, the bivalent IgGs have significantly greater effective affinities due to avidity.
shMFE IgG (Kd = 44.7 pM) binds approximately 110 fold higher than the monovalent variant,
while sm3E IgG (Kj = 6.4 pM) binds 3.5 fold tighter than ds(sm3E)-Fc. The smaller affmity
difference between monovalent and bivalent sm3E stems from the fact that monovalent
dissociation of this molecule is already extremely slow.
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Figure 4.3 - Kd titrations of IgG and ds(Fv)-Fc variants. Unlabeled proteins were incubated with
fixed LSl74T cells for 24 hours at 374C, and binding measured by flow cytometry with a Protein
A-488 secondary. The measured Kd values are as follows: sm3E IgG = 6.4 pM, ds(sm3E)-Fc =
22.7 pM, shMFE IgG = 44.7 pM, and ds(shMFE)-Fc = 4.96 nM
4.3.3 - Radiolabeled antibody biodistribution
To compare bulk tumor uptake and biodistribution, antibodies were radiolabeled with
"'In and injected at a 100 ptg dose into nude mice bearing CEA positive LS174T tumors and
CEA negative C6 tumors. Plasma clearance and tissue accumulation were assessed by gamma
counting. Both ds(shMFE)-Fc and ds(sm3E)-Fc are cleared from the plasma with faster kinetics
than their cognate IgG molecules (Figure 4.4). The difference is mainly in the beta phase with p-
elimination half times of 28.6 hours for sm3E IgG, 19.4 hours for ds(sm3E)-Fc, 35.3 hours for
shMFE IgG, and 11.8 hours for ds(shMFE)-Fc. Faster clearance of ds(Fv)-Fc molecules appears
to be mediated largely through increased renal filtration with significant accumulation in the
kidneys at 24 hours (Figure 4.5). In an unexpected result, both ds(shMFE)-Fc and shMFE IgG
were cleared faster than the corresponding sm3E variants despite sequences that differ at only
three residues. Increased shMFE clearance occurred primarily in the alpha-phase and may
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reflect some previously uncharacterized difference in stability or aggregation between the two
variable domains.
Specific accumulation of all antibodies in the CEA-expressing LS 1 74T xenograft was
observed at 24 hours with concentrations of 23.08, 17.82, 12.0 and 11.82 %ID/g for sm3E IgG,
ds(sm3E)-Fc, shMFE IgG, and ds(shMFE)-Fc, respectively. When accounting for mouse to
mouse variability, there was no statistically significant difference in tumor uptake between the
two ds(Fv)-Fc fragments and their corresponding IgGs. Mechanistically, the equivalent tumor
uptake of the two formats may be a product of greater capillary permeability and void fraction of
the smaller ds(Fv)-Fc fragments offsetting their faster plasma clearance. The lower tumor levels
for shMFE IgG and ds(shMFE)-Fc compared to the sm3E variants is likely due to the faster
plasma clearance kinetics of these constructs. The lower affinity of the shMFE variable domain
may also reduce tumor uptake, although it's unlikely in this case as shMFE IgG is closer in
effective affinity to the sm3E variants than it is to ds(shMFE)-Fc. Uptake in the negative C6
tumor was approximately half that in the positive tumor for all constructs at 24 hours. The
significant uptake in the negative tumor is a result of enhanced permeability and retention (EPR)
effects, and is in line with previously described predictions for non-specific tumor uptake of
IgGs (16).
Computational models simulating total tumor uptake as a function of mechanistic
parameters including size and affinity have been described previously (16,17). To compare these
model predictions to our experimental results, targeting simulations were performed for all
constructs as described in the methods. Parameters were either measured experimentally (A, B,
a, p, R-ogh) or taken from the literature (16). Notably, no parameters were fit to the
experimental results. At 24 hours, the model reasonably predicts the relative tumor levels of
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each construct with similar uptake for each IgG and ds(Fv)-Fc pair and lower uptake for the two
shMFE constructs relative to sm3E (Figure 4.6A). In extended time course simulations, the
model predicts that the IgGs will have higher uptake than the corresponding ds(Fv)-Fcs at later
time points due to the slower p-phase clearance (4.6B).
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Figure 4.4 - Plasma clearance of "'In labeled proteins in tumor bearing mice. Plasma samples
were collected from the tail vain at various times following a 100 tg bolus dose and the
radioactivity measured by gamma country. The blood concentrations were fit to the
biexponential decay equation [Ab](t) = Ae-a + Be~' to derive the clearance rate constants.
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Construct (%ID/mL) (Urs) (%ID/mL) (1
sm3E IgG 5.3 0.16 20.7 28.60
ds(sm3E)-Fc 7.9 0.15 18.1 19.44
shMFE IgG 10.6 0.15 15.4 35.31
ds(shMFE)-Fc 5.9 0.12 20.1 11.77
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Figure 4.5 - 24 hour biodistribution of "'In labeled proteins. Mice containing CEA-positive
LS174T and CEA-negative C6 tumors were injected with 100 ptg "'In labeled antibodies. At 24
hours, the mice were sacrificed, tissues resected, and the radiation in each measured by gamma
counting.
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Figure 4.6 - Comparison of computational predictions and experimental results. Simulations
were performed using a mechanistic compartmental model as described in the methods. A:
Experimental values and computational predictions of antibody uptake in LS 1 74T tumor
xenografts at 24 hours. B: Computational predictions of antibody tumor uptake over time.
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4.3.4 - Immunoflourescent measurement of antibody microdistribution
Antibody microdistribution within the tumor xenografts was assessed by
immunofluorescent microscopy. 100 ig of unlabeled antibody was injected into mice bearing
LS174T tumors. At 24 hours post-injection, the tumors were excised, cryosectioned, and stained
for antibody, blood vessel, and cell nuclei localization (Figures 4.7 and 4.8). Both sm3E IgG and
ds(sm3E)-Fc accumulate heterogeneously in the tumor with areas of intense staining around
blood vessels and sharp boundaries between targeted and untargeted cells. shMFE IgG also
exhibits intense and heterogeneous labeling of perivascular cells, although there are also areas of
more diffuse staining distal to the capillaries. In contrast to the other molecules, the low affinity
construct ds(shMFE)-Fc is distributed homogeneously with a low level of staining throughout
the tumor.
As with the antibody macrodistribution, computational models can be used to predict
antibody microdistribution around a capillary (Figure 4.9A). Simulations were performed using
parameters measured experimentally or taken from the literature as described in the methods.
The model predicts that ds(shMFE)-Fc will have a relatively flat antibody gradient with low
levels of accumulation throughout the tumor. In contrast, the model predicts that both IgGs and
ds(sm3E)-Fc will have a sharp transition between fully saturated cells near the capillary and fully
untargeted cells further into the tumor. The different distributions are a function of affinity as
ds(shMFE)-Fc is able to dissociate from the antigen following binding and diffuse further into
the tumor, while the three clones with high functional affinity are effectively bound irreversibly.
Image analysis performed on Figure 4.7 shows that the experimental antibody
concentrations follow a similar trend to the computational predictions (Figure 4.9B). Both high
affinity sm3E variants have high levels of labeling near the capillary but no signal above
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background -200 tm into the tumor. ds(shMFE)-Fc has a flatter gradient with lower labeling
intensity near the vessel, but a higher signal at points distal to the capillary. shMFE IgG has a
unique trendline in which it follows a similar distribution to sm3E IgG and ds(sm3E)-Fc over the
first 100 tm from the capillary but has a significantly higher intensity at distances approaching
200 im. This result may be partially artifactual given the low number of points at these larger
distances, but it may also be due to some monovalent binding of the shMFE IgGs that allows for
greater tumor penetration.
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Figure 4.7 - Antibody microdistribution in tumor xenografts. 100 pg of unlabeled antibody was
injected into mice bearing LS174T tumors. Tumors were excised, sectioned, and stained as
described in the methods. The injected antibodies were imaged with anti-Human Fc-488 (green),
blood vessels with anti-CD31 (red), and cell nuclei by DAPI (blue). While not shown, CEA
antigen was imaged with an anti-CEA antibody and is present throughout each tumor. In
general, sm3E IgG, ds(sm3E)-Fc, and shMFE IgG have highly heterogeneous uptake with
intense staining around the blood vessels and areas of untargeted cells. In contrast, ds(shMFE)-
Fc is distributed homogeneously with a low level of staining throughout the tumor. Antibody
distribution was also influenced by variable degrees of cellular necrosis between the different
tumor xenografts. In particular, the center of the sm3E IgG tumor and two outer lobes of the
shMFE IgG tumor are largely necrotic. Scale bar = 1 mm.
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Figure 4.8 - Antibody microdistribution in tumor xenografts. The images are the same as in
Figure 4.7 but presented at a higher magnification. The DAPI channel has been removed to
make the antibody channel (green) and vessel channel (red) more visible. In general, there are
cells and antigen located throughout the presented fields (data not shown). Scale bar = 200 pm.
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Figure 4.9 - Comparison of experimental microdistribution and computational predictions. The
model accurately predicts that ds(shMFE)-Fc will have a flatter gradient of antibody uptake as a
function of distance from the capillary compared to the other three constructs. Computational
predictions were performed by numeric simulation as described in the methods. For analysis of
experimental data, ImageJ was used to convert the capillary distribution images to Euclidean
distance maps in which each pixel is assigned a number from 0-255 representing the distance to
the closest blood vessel. Necrotic sections and the outer border of each tumor slice were
assessed by H & E and DAPI staining and removed from the analysis by masking. The average
signal intensity of the antibody channel was calculated for each Euclidean distance using the
regionprops method in Matlab. Distances were converted from pixels to microns using the ratio
1 pixel = 1.33 microns.
4.4 - Discussion
IgG antibodies remain the dominant format for tumor targeting due to their high
functional affinity, slow plasma clearance, and high tumor uptake. However, the relatively large
size of these molecules may limit capillary extravasation, while the high affinity bivalent binding
reduces antibody penetration. Therefore, we hypothesized that a smaller, monovalent antibody
fragment that maintained slow plasma clearance through the Fc domain may have increased
tumor uptake and more homogeneous distribution.
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To test this hypothesis, a novel 79 kDa ds(Fv)-Fc molecule was developed consisting of a
single disulfide stabilized Fv domain linked to a heterodimeric Fc. The format is similar to a
previously described 105 kDa one armed anti-c-Met antibody composed of a full light chain and
heavy chain paired with a truncated Fc (18,19). Anti-CEA ds(Fv)-Fc molecules based on the
low affinity variable domain shMFE (K = 8.5 nM) and high affinity variable domain sm3E (Kd
= 30 pM) were produced in Hek cells. Using sequential His and FLAG tag affinity
chromatography, the molecules were purified at yields roughly half that of the full length IgG.
The reduced yield is due to competitive formation of ds(Fv)2-Fc homodimers. It may be possible
to improve the yield of the desired trimeric species by inserting mutations into the CH3 domain
that encourage heterodimer formation (20,21). The purified ds(Fv)-Fc molecules bind to
LS 1 74T cells with monovalent affinities similar to those measured previously for yeast
produced ds(scFv) fragments, while the bivalent IgG molecules have significantly higher
affinities as expected due to avidity.
To assess the in vivo biodistribution of the ds(Fv)-Fc antibody fragments relative to IgGs,
the proteins were labeled with 'In and injected into nude mice bearing C6 and LS174T tumors.
For both variable domains, the ds(Fv)-Fc molecules were cleared from the plasma more rapidly
than the corresponding IgGs. This faster plasma clearance appears to be driven largely by renal
filtration as both ds(Fv)-Fc molecules accumulate in the kidneys at higher levels than either IgG.
Although the kidney cutoff is often described as occurring at 60 or 70 kDa (22), these results
indicate that larger molecules can still be filtered slowly over time. Unexpectedly, both
ds(shMFE)-Fc and shMFE IgG were cleared from the plasma faster than their sm3E based
counterparts. This may reflect lower stability or increased aggregation of the shMFE based
antibodies. Previous studies using scFv and PEGylated scFv variants of shMFE and sm3E
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showed no difference in clearance between the two clones (data not shown), although in those
cases clearance may have been too fast to observe different stability effects.
Despite the faster plasma clearance of the ds(Fv)-Fc molecules compared to the IgG,
there was no statistical difference in the tumor uptake levels of the two formats at 24 hours post
injection for either variable domain. One potential explanation for this result is that greater
extravasation of the smaller ds(Fv)-Fc proteins into the tumor offsets the faster plasma clearance.
Size-dependent trends in permeability and void fraction suggest that the 79 kDa ds(Fv)-Fc
format should extravasate -25% faster and have a -20% greater available volume fraction in the
tumor compared to the 150 kDa IgG (16). Modeling simulations using the experimentally
measured plasma clearance rates and predicted permeability and void fraction values reproduce
the experimental targeting results, supporting this hypothesis.
Although we believe that this is the first description of the monovalent ds(Fv)-Fc format,
other antibody fragments containing the full Fc domain have been described. In particular,
bivalent scFv-Fc molecules (MW ~ 105 kDa) lacking the CHI domain have been generated as
tumor targeting agents against a number of antigens. In one example, an anti-TAG-72 scFv-Fc
molecule was described with similar plasma clearance kinetics to the full IgG and significantly
higher peak tumor uptake (57.7% ID/g vs. 39% for the IgG) (23). In contrast, an anti-CEA scFv-
Fc was cleared from the blood approximately twice as fast as the cognate IgG and had a
corresponding decrease in tumor uptake (20 %ID/g vs. 30% ID/g for IgG) (24). Although they
do not contain a Fc domain, antibodies linked to albumin either covalently or non-covalently also
experience reduced plasma clearance due to FcRn mediated salvage and increased tumor uptake.
In one example, an anti-HER2 Fab fragment fused to an albumin binding peptide had similar
peak tumor uptake values compared to the full IgG (2). Overall, it appears that the tumor uptake
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efficiency of smaller, FcRn binding antibody fragments relative to the IgG varies between
constructs and is largely dependent on the rate of plasma clearance. In cases where clearance is
similar to the IgG, the smaller molecules have comparable or even improved tumor uptake, likely
due to higher permeability.
In microdistribution studies, the three constructs with high functional affinity sm3E IgG,
ds(sm3E)-Fc, and shMFE IgG all had heterogeneous uptake with intense perivascular staining,
while ds(shMFE)-Fc was distributed homogeneously with less intense cell labeling throughout.
Differences in microdistribution as a function of affinity have been well characterized both
computationally and experimentally (25-30). In the most analogous case, switching from a
bivalent anti-HER2 IgG to a monovalent Fab with an albumin binding peptide significantly
increased tumor penetration in mouse xenograft studies (2). While high affinity antibodies
including most bivalent IgGs are effectively bound irreversibly, low affinity, monovalent
antibodies are able to dissociate prior to internalization and continue diffusing into the
tumor (31). At the same time, however, low affinity antibodies suffer from decreased antigen
saturation per cell and potentially faster clearance from the tumor. Ultimately, the relevant
effectiveness of using high or low affinity antibodies will depend on the cytotoxic effector.
Potent, short-range effectors like alpha-emitting radionuclides and drug conjugates may be
ideally paired with low affinity agents like ds(shMFE)-Fc, while less potent drugs or molecules
with significant bystander effects may be most effective with high affinity antibodies.
Notes - The radiolabeled biodistribution studies were performed by Kelly Davis. The histology
studies were performed in large part by John Rhoden.
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Chapter 5 - MMP-2 activatable antibodies for improved tumor specificity
5.1 - Introduction
Monoclonal antibodies have become an important class of cancer therapeutics with nine
FDA approved drugs and dozens more in clinical trials (1). By specifically targeting antigens
overexpressed in tumor tissues, these agents typically have reduced side effects compared to
classical chemotherapeutics. However, the presence of low levels of target antigen in healthy
tissues can still present clinical problems. Several common tumor targets are present to some
degree in healthy tissues including epidermal growth factor receptor-1 (EGFR) expression in the
epidermis of the skin and A33 expression throughout the colon (2,3). Other tumor antigens
including carcinoembryonic antigen (CEA) are shed into the blood stream where they provide an
additional off-target depot (4).
Antibody binding in these healthy tissues can induce toxicity by recruiting immune
effectors or blocking receptor activity. Anti-EGFR antibodies, for instance, produce a
characteristic papulopustular rash and other side-effects due to disrupted receptor signaling in the
epidermis (5). While generally mild, these toxicities lead to dose modifications or suspended
treatment in 8-17% of patients (5). Off-target binding may also alter the pharmacokinetics of the
antibody, particularly in cases of low antibody dose or high antigen concentration. This function
is especially likely for shed antigens that accumulate in the blood due to the highly accessible
nature of this compartment for iv administered antibodies (6). By binding to the blood pool of
antigen, the amount of free antibody is reduced, which can in turn decrease tumor uptake and
penetration. Finally, antibody binding to non-tumor antigen can lead to high background in
imaging or diagnostic studies.
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An ideal antibody drug would therefore have additional mechanisms to provide
specificity for antigen molecules expressed in the tumor tissue versus those expressed by healthy
cells. One approach for imparting additional tumor specificity is to exploit matrix
metalloproteinases (MMPs), a family of proteases that are highly expressed in a broad range of
tumor types. MMPs are synthesized by both tumor and stromal cells, and are involved in cell
growth, cell migration, metastasis, and angiogenesis (7). Due to their tumor selective
overexpression, MMPs have been used as activating agents for a variety of tumor imaging and
therapeutic modalities including toxins, fluorogenic imaging agents, doxorubicin prodrugs, and
self-assembling nanoparticles (8-11). More recently, two groups have produced MMP-
activatable antibodies and other binding ligands by fusing either a fragment of the target antigen
or a synthetic blocking peptide to the antibody through an MMP cleavable linker (12,13). In
both cases, antibody masking depends on a specific, molecular interaction between the blocking
domain and antigen binding site.
Here we describe an alternative strategy for engineering MMP-2 activatable antibodies in
which two halves of a coiled-coil heterodimer are fused to the N-termini of the antibody light
and heavy chains through MMP-2 cleavable linkers (Figure 5.1). The coiled-coil forms a clasp
over the antibody binding site that sterically blocks antigen-antibody interactions. Following
MMP-2 cleavage, the coils are removed and full binding activity is restored.
5.2 - Methods
Plasmid construction
Plasmids encoding all constructs were produced using standard molecular biology techniques
including PCR amplification, Quikchange PCR, and digestion/ligation. For the yeast surface
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displayed proteins, Fab fragments of the sm3E IgG light chain and heavy chain were PCR
amplified from the gWiz vectors described in Chapter 4 using primers that inserted N-terminal
NheI and BamHI sites. The FabL PCR product was ligated into a prs314 yeast secretion vector
with a C-terminal His-tag, while the FabH product was ligated into a prs316 vector with a C-
terminal cAga2 fusion. Oligonucleotides encoding 3-6 repeats of the K and E coils were
generated by DNA synthesis or PCR amplification and inserted at the N-termini of the Fab
vectors cut with NheI and BamHI. For the soluble, yeast produced ds(Fv) fusions, an
interdomain disulfide bond was introduced by mutating specific variable domain framework
residues to cysteines as described previously (14). The variable domain fragments were then
PCR amplified with primers that introduced an N-terminal MMP-2 cleavable linker or scrambled
linker sequence. The amplified ds(Fv)L sequence was ligated into a prs314 vector with a C-
terminal His tag, while the ds(Fv)H sequence was ligated into a prs316 vector with a C-terminal
FLAG tag. Primers encoding the VelA1 and VelB 1 coils were synthesized and ligated N-
terminal to the linkers in NheI/BamHI cut vectors. N-terminal cysteine residues were inserted by
Quikchange mutagenesis. For the Hek produced Fc fusions, the coil and linker sequences were
amplified from the yeast vectors and inserted at the N-terminus of the ds(shMFE)L and
ds(shMFE)H-Fc gWiz vectors described in Chapter 4. The final amino acid sequences of all
constructs described in this chapter are presented in Appendix A.
Yeast surface displayed mmp-antibody binding
Combinations of K3-6-FabL and E3-6-FabH-cAga2 fusion constructs were co-transfected into
JAR200 yeast using the EZ-yeast kit (Zymo research) and selected on SD-CAA plates. Colonies
were inoculated and grown in 5 mL SD-CAA liquid media at 300C overnight. Cells were then
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pelleted, resuspended at an OD 60 0 ~ 1 in 5 mL of YPGAL media, and incubated at 20*C for 48
hours. Antibody display was confirmed by labeling cells with Alexa-488 conjugated anti-His
IgG (Anaspec) diluted 1:200 and measuring fluorescence by flow cytometry. For binding
titrations, cells were incubated with soluble CEA (Fitzgerald Industries) at a range of
concentrations in PBS + 0.1% BSA at 37*C. A sufficient volume was used to maintain a 10 fold
excess of CEA over surface displayed antibody throughout. After 24 hours of incubation, cells
were pelleted and washed with 1 mL ice cold PBS-BSA. The cells were then resuspended in 200
ptL of M85151 a (Fitzgerald Industries), a non-competitive anti-CEA mouse IgG diluted 1:1000,
and incubated on ice for 30 minutes. After another PBS-BSA wash, cells were resuspended in
200 pL goat anti-mouse-488 (Invitrogen) diluted 1:200 and incubated on ice for 20 minutes.
Cells were pelleted and run on an EPICS Coulter XL cytometer (Beckman Coulter) to measure
the 488 signal. The signal was fit to the equation MFU = Bmax ([Ab]/([Ab]+Ka)) to determine the
Kd.
Secretion and purification of soluble proteins
Plasmids encoding the coiled-coil-ds(Fv) fusions were transformed into the YVH10 strain of
yeast using the EZ-Yeast Kit (Zymo Research) and plated on SD-CAA. Individual colonies
were grown in shaker flasks with 125 mL SD-CAA liquid media to an OD 600 of 5-7, then
pelleted and resuspended in YPGAL media at 20*C to induce secretion. After 48 hours, cells
were pelleted and the cleared supernatant adjusted to a pH of 7.4. The His-tagged fusion
proteins were purified using Talon metal affinity resin (Clontech) according to the
manufacturer's batch-column protocol. To remove dimers and other aggregates, proteins were
further purified by size-exclusion chromatography with Superdex-200 and Superdex-75 columns
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(GE Healthcare) connected in series using TBS (50 mM Tris, 150 mM NaCl, pH 7.4) as the
mobile phase. For secretion of coiled-coil-ds(Fv)-Fc fusions, 333 pg of each plasmid were
transiently transfected into Hek cells using PEI as the transfection reagent as described in
Chapter 4. Cells were incubated at 370C on a roller for 8 days, at which time the supernatant was
cleared and the proteins purified by sequential anti-His and anti-FLAG chromatography.
Aggregates were removed by size-exclusion chromatography as described above.
In vitro MMP cleavage
Purified MMP-2 (Anaspec) was activated with 10 mM 4-Aminophenylmercuric acetate (APMA)
(Sigma Aldrich) in TBS with 5 mM CaCl 2 for 1 hour at 370C. Coiled-coil masked antibodies at
a concentration of 1 pM were incubated with activated MMP-2 at a final concentration of 200
U/mL in TBS + 5 mM CaCl 2 at 37*C for 2 - 24 hours. Cleavage was stopped by addition of
EDTA to a final concentration of 50 mM and chilling the reactions on ice. Samples were run on
12% Bis-Tris gels and stained with SimplyBlue SafeStain (Invitrogen) to assess the extent of
cleavage. To test cleavage specificity, samples were incubated with the MMP-2 inhibitor
Galardin (BIOMOL International, Inc.) at a final concentration of 10 mM.
Soluble protein binding titrations
CEA expressing LS 174T cells were trypsinized and fixed with Cytofix buffer (BD Pharma) for
20 minutes at 40C to prevent internalization. The fixed cells were incubated with cleaved or
uncleaved antibodies at various concentrations in PBS + 0.1% BSA using sufficient volumes to
ensure at least a 10 fold molar excess of antibody. For the cleaved samples, the antibodies were
incubated with 200 U/mL activated MMP-2 overnight at 25"C prior to mixing with the cells.
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Binding incubations were performed at 370C for 24 hours, after which the cells were pelleted and
washed with cold PBS-BSA. The pelleted cells were resuspended in anti-FLAG-phycoerythrin
(Prozyme Inc.) diluted 1:500 in PBS-BSA and incubated on ice for 20 minutes. Labeled cells
were run on an EPICS Coulter XL cytometer to measure PE fluorescence and the Kd values fit as
described above.
5.3 - Results
MMP activatable antibodies have potential for improving the specificity of tumor
targeting by reducing binding to antigen molecules expressed in healthy tissue. Here, we
describe a method for making MMP-2 activatable antibody fragments by sterically blocking
antibody-antigen interactions with a coiled-coil masking domain that is removed by protease
cleavage (Figure 5.1).
Antigen coilA-mmp-ds(Fv)LncoilB-mmp-ds(Fv)H
Antigen
MMP-2
"Masked" "Unmasked"
Figure 5.1 - Schematic of MMP-2 activatable antibodies. In the masked state, the heterodimeric
coiled-coil forms a clasp over the binding site that blocks antigen binding. The coil is stabilized
by an N-terminal disulfide bond. MMP-2 cleaves the linker sequences (denoted by dashed lines)
such that the coils are removed and full antigen binding is restored.
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5.3.1 - CEA binding to yeast surface displayed fusions
We first tested the ability of N-terminal coiled-coil domains to sterically block antigen
binding using yeast surface displayed anti-CEA antibody fragments (15). Fab fragments of the
anti-CEA clone sm3E with or without N-terminal coiled-coil domains were fused to cAga2 and
displayed on the surface of yeast. For the coils, we utilized a synthetic system in which the
complementary heptamers KVSALEK (K-coil) and EVSALKE (E-coil) were repeated 3-6 times
at the N-terminus of the Fab light and heavy chains, respectively (Sequences A. 14 and A. 15 in
the Appendix). By including a range of repeat lengths, we were able to vary the stability of the
coiled-coil heterodimer from AG = -6.41 kcal/mol for 3 repeats to AG = -18.08 for 6
repeats (16). A short linker sequence (GSGGGGS) was included between the coiled-coil and
variable domains.
As expected, the addition of heterodimeric coiled-coils to the N-termini of the light and
heavy chains significantly reduces the binding affinity of the sm3E Fab for soluble CEA. The
addition of 3, 4, 5, or 6 repeat coiled coils produced a 3 fold, 20 fold, 75 fold, or 178 fold
decrease in binding affinity, respectively (Figure 5.2). The decrease in affinity is mediated
almost entirely through a reduction in the association rate (kon), with little to no change in the
dissociation rate (konf) (data not shown). The trend of decreasing affinity with increased number
of repeats suggests that the blocking mechanism is dependent on the size and/or stability of the
coiled-coil heterodimer. To directly test the importance of heterodimer formation between the K
and E coils, we surface displayed Fabs containing two E5 coils with no K5 coil or one K5 coil
with no E5 coil. Both constructs bind only 2-3 fold slower than the unmasked Fab, suggesting
that blocking is not due to a specific interaction between either of the coil halves alone with the
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antibody binding site and is instead dependent on formation of the coiled-coil heterodimer
(Figure 5.2).
10~1 10- 10- 10- 10 8 10-7
Concentration (M)
- Fab
- K3/E3-Fab
- K4/E4-Fab
- K5/E5-Fab
K6/E6-Fab
- E5/E5-Fab
- K5-Fab
Figure 5.2 - Binding titrations for soluble CEA to yeast surface displayed coiled-coil-Fab
fusions. A: cAga2 fusion variants of the anti-CEA Fab sm3E with or without N-terminal coiled-
coil domains were displayed on the surface of yeast and incubated with soluble CEA. Binding
was measured by flow cytometry using a non-competitive anti-CEA secondary and goat anti-
mouse-488 tertiary label. The addition of complementary K and E coils to the light and heavy
chains, respectively, leads to a significant decrease in binding affmity dependent on the number
of repeats. In contrast, minimal blocking is observed with E5 coils fused to both the light and
heavy chains, or a single K5 domain fused to the light chain with no corresponding E5 coil on
the heavy chain. We were unable to express the K5/K5 pair at sufficient levels to measure
binding.
5.3.2 - Soluble protein production and cleavage
To generate soluble, MMP-2 activatable antibody fragments, the heterodimeric coiled-
coil sequences were fused to the N-termini of anti-CEA disulfide stabilized variable domains
(ds(Fv)s) through MMP-2 cleavable linkers (linker sequence - IPVSLRSG) (17). As a control,
constructs were built in which the MMP-2 linker was replaced by a scrambled sequence
(IPLSRSVG). The K and E coiled-coils were secreted poorly in this soluble format (data not
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Construct Kd (pM) Fold
change
Fab 15.9 ± 9.2
K3/E3-Fab 52.9 ± 8.0 3.3
K4/E4-Fab 319.7 ±71.5 20.1
K5/E5-Fab 1188 ± 372.5 74.8
K6/E6-Fab 2830 + 1680 178.0
E5/E5-Fab 42.7 ± 9.1 2.7
K5-Fab 47.0 ± 5.4 3.0
..... . ...
............ 
shown) so an alternative coiled-coil heterodimer pair VelA1/VelB1 was used instead (18). This
coiled-coil has similar thermodynamic properties to the K5/E5 pair with AG = -11.6 kcal/mol,
but a better balanced charge distribution leading to higher protein expression. Cysteine residues
were added at the N-termini of the two coiled-coil halves to form a disulfide bond that further
stabilizes the coil and prevents the formation of daisy-chains and other aggregates. To test the
ability of the coiled-coil domain to mask both high affinity and low affinity antibodies, soluble
constructs were built using two different anti-CEA variable domains: sm3E (K = 30 pM) and
shMFE (K1 = 8.5 nM). The sequences are listed in Appendix A, and all VelA1/VelBl-ds(Fv)
fusion proteins are hereafter referred to as mmp-ds(Fv) or scr-ds(Fv) for constructs containing
the MMP-2 cleavable or scrambled linker, respectively.
Fusion proteins were secreted in yeast cells and purified by a combination of anti-His and
size-exclusion chromatography. Final yields ranged from 1-2 mg per liter of secretion. The His-
purified heterodimers were >90% monovalent, and the remaining aggregates were efficiently
removed by size-exclusion chromatography (data not shown).
To check that the substrate linker was efficiently and specifically cleaved, the coiled-coil
masked antibodies were incubated with recombinant MMP-2 at a concentration of 200 U/mL.
This enzyme concentration is -1/2 the level measured in HT-1080 tumor xenografts in vivo (9).
The MMP-2 cleavage is efficient as nearly all of a 1 pM protein solution is fully unmasked
within 8 hours (Figure 5.3A). The cleavage is also highly specific as the scrambled linker
constructs remain fully intact even after overnight incubation with the enzyme (Figure 5.3B).
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Figure 5.3 - MMP-2 linker cleavage. A: Time course of MMP-2 cleavage. Mmp-ds(sm3E) was
incubated with 200 U/mL recombinant MMP-2 at 370C and the amount of cleavage assessed on
a 12% SDS-PAGE gel. Over time, the 39 kDa fusion product is cleaved into a 27 kDa ds(Fv)
domain and 12 kDa coiled coil. The higher molecular weight band seen at intermediate cleavage
time points represents fusion proteins in which one but not both of the MMP-2 linkers have been
cleaved giving the protein a more open conformation that runs at a larger size. The addition of
the MMP-2 inhibitor galardin eliminates all cleavage. B: Specificity of MMP-2 cleavage.
Constructs containing either the MMP-2 cleavable or scrambled linker were incubated with
recombinant MMP-2 overnight. The scrambled linker constructs remain fully intact.
5.3.3 - MMP-2 dependent binding
After confrming that the fusion proteins were specifically cleaved, we tested the antigen binding
properties of the molecules on fixed CEA-expressing LS 1 74T cells. Binding of each construct
was measured both before and after complete cleavage with 200 U/mL recombinant MMP-2.
mmp-ds(sm3E) binds 300 fold faster following MMP-2 treatment with a Kd shift from 10.6 nM
to 35 pM (Figure 5.4A, Table 5.1). The unmasked binding affinity is nearly identical to previous
measurements of monovalent sm3E affinity suggesting that full binding activity is restored
following cleavage (19). Similarly, mmp-ds(shMFE) binds 272 fold faster following cleavage
with a shift from 1.7 pM to 6.4 nM. The post-cleavage K1 is again similar to previous
measurements of shMFE affinity (19). In contrast, the two scrambled linker fusions have no
significant change in binding affinity after MMP-2 treatment, indicating that the increased
binding is dependent on linker cleavage (Table 5.1).
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Figure 5.4 - Binding titrations for mmp-ds(sm3E) (A) and mmp-ds(shMFE) (B) before and after
MMP-2 cleavage. The titrations were performed on fixed LS 1 74T cells as described in the
Methods section. For both variable domains, there is a significant increase in binding affmity
following MMP-2 cleavage.
Construct Kd (-MMP2) Kd (+MMP2) Fold change
mmp-sm3E 10.6 ±0.9 nM 35.3 8.1 pM 300
scr-sm3E 11.0 ±4.9 nM 5.82 0.8 nM 1.9
mmp-shMFE 1.74±0.1 pM 6.38 1.6 nM 272
scr-shMFE 1.83±0.1 pM 2.34 0.1 pM 0.8
Table 5.1 - Binding affinities for coiled-coil masked anti-CEA ds(Fv)s with MMP-2 cleavable
(mmp) or scrambled (scr) linkers before or after cleavage with 200 U/mL MMP-2.
5.3.4 - MMP-activatable Fc conjugates
In preparation for future in vivo studies, the constructs were reformatted as monovalent
Fc fusions analogous to the ds(Fv)-Fc molecules described in Chapter 4 (Figure 5.5A). The
disulfide stabilized VelA1/VelB1 coiled coil was fused to the N-terminus of ds(shMFE)-Fc
through either an MMP-2 cleavable or scrambled linker. We used ds(shMFE)-Fc as the antibody
domain instead of ds(sm3E)-Fc because the modeling work in Chapter 2 suggested that the
affinity switch from pre-cleaved ds(sm3E)-Fc (Kd = 10.6 nM) to post-cleaved (K. = 35.3 pM)
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would have no significant effect on total tumor uptake. In contrast, the ds(shMFE)-Fc switch
from 1.74 pM to 6.4 nM was predicted to produce significantly greater tumor uptake after
cleavage.
The coiled-coil fusions mmp-ds(shMFE)-Fc and scr-ds(shMFE)-Fc, along with the
unmasked fragment ds(shMFE)-Fc, were secreted in Hek cells and purified by sequential His,
FLAG, and size exclusion chromatography (Figure 5.5B). In SDS-PAGE analysis, the mmp-
ds(shMFE)-Fc molecule shifts down to the size of the unmasked protein following MMP-2
treatment, while the scr-ds(shMFE)-Fc molecule remains unchanged (Figure 5.5C). Cleavage of
mmp-ds(shMFE)-Fc leads to increased binding on LS 1 74T cells, while the scrambled linker
variant remains blocked (Figure 5.5D).
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Figure 5.5 - Production and characterization of coiled-coil ds(Fv)-Fc fusions. A: Schematic of
mmp-ds(Fv)-Fc with coiled-coil masking domain fused at the N-terminus of the variable
domains. B: Coomassie stained gel of antibody fragments demonstrating size and purity. C:
anti-FLAG western blot of antibody fusions following MMP-2 treatment. The mmp-ds(shMFE)-
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Fc construct is reduced to the size of unmasked ds(shMFE)-Fc following cleavage, while the scr-
ds(shMFE)-Fc construct is unchanged. D: Binding of masked constructs following MMP-2
cleavage. The MMP-2 cleavable linker constructs bind to a significantly greater extent following
MMP-2 cleavage while the scrambled linker constructs are unchanged.
5.3.5 - Extension to other targets
One of the expected advantages of a steric blocking approach compared to a blocking
mechanism dependent on specific interactions between the masking domain and antibody
binding site is that the masking domain should be generalizable to a range of antibodies and
targets. To test this prediction, we built coiled-coil mmp-ds(Fv) fusions in which the anti-CEA
variable domains were replaced by the variable domains of 806, an anti-EGFR antibody, or A33,
an anti-A33 antibody. EGFR and A33 were selected as targets as both antigens have significant
normal tissue expression in the skin epidermis and colon, respectively.
The fusion constructs were secreted in yeast and purified as above. An additional anti-
FLAG purification step was required for the mmp-ds(A33) molecule to remove some light chain
dimers. Both the anti-EGFR and anti-A33 fusions were efficiently cleaved by MMP-2 (data not
shown). In binding assays on EGFR expressing A43 1 cells or A33 expressing LS174T cells,
both antibody constructs bind the cells to a significantly greater extent following MMP-2
treatment (Figure 5.6).
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Figure 5.6 - Binding of coiled-coil masked anti-A33 or anti-EGFR antibody fragments before or
after cleavage with 200 U/mL MMP-2. Binding was measured on A33-expressing LS174T cells
or EGFR-expressing A431 cells, respectively, by flow cytometry with anti-FLAG-PE secondary.
Both constructs bind antigen expressing cells to a significantly greater degree following protease
cleavage.
5.4 - Discussion
Antibody binding to antigen depots in healthy tissue can lead to toxicity, altered
pharmacokinetics, and high imaging background. Here we describe an approach for avoiding
off-target binding and increasing tumor specificity by engineering antibodies that bind their
target antigen only after cleavage by the tumor expressed protease MMP-2. In our system, two
halves of a coiled-coil heterodimer are fused to the N-termini of the antibody light and heavy
chains through MMP-2 cleavable linkers. As the coiled-coil forms, it brings the two halves into
position proximal to the antibody binding site in a manner that sterically blocks antigen binding.
We demonstrate that the coiled-coil domain reduces binding of anti-CEA antibodies to
CEA-expressing cells up to 300 fold, with full binding activity restored following MMP-2
cleavage. The extent of blocking is nearly identical for low and high affinity anti-CEA clones.
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The MMP-2 dependent binding increase is also specific as molecules with scrambled linkers
show no difference in affinity following protease treatment. The low level of fusion protein
binding in the uncleaved state is likely a function of sufficient linker flexibility and coiled-coil
breathing at the linker interface to allow rare instances of antigen binding.
Recently, two groups described the production of MMP activatable antibodies and other
binding ligands by attaching a blocking domain with specific affinity for the antibody binding
site through a MMP-2 cleavable linker (12,13). While this specific-blocking approach can be
effective, we believe that it has two limitations. First, since masking depends on specific
molecular interactions between the blocking domain and binding site, a new blocking domain
must be selected or engineered for each unique antibody variable domain. Second, since the
blocking domain has intrinsic affinity for the binding site, it may continue to function as an
inhibitor even after linker cleavage. In contrast, the steric blocking domains described here have
no specific affinity for the binding site. As a result, they should be transferable to an array of
antibodies with similar blocking activity. In this work, we demonstrate that MMP-2 activatable
antibodies can be generated against the target antigens CEA, EGFR, and A33 using the same N-
terminal coiled-coil masking domain. Similarly, the coiled-coils should have no inhibitory
activity following cleavage.
The steric blocking approach described here is also flexible in regards to the masking
domain as two different coiled-coil systems (K/E and VelAl/VelB1) efficiently block antibody
binding. It's likely that other heterodimeric domains such as Fv dimers will also exert a masking
functionality. Blocking is also largely independent of the linker sequence as constructs with a
Gly-Ser linker (GSGGGGS), MMP-2 cleavable linker (IPVSLRSG), scrambled linker
(IPLSRSVG), and other MMP-2 cleavable sequences (GPLGVRG, data not shown) have similar
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masking properties. As a result, we believe that the system should be generalizable to linkers
cleaved by other MMPs or tumor proteases such as Cathepsin B, providing an additional
mechanism for tuning antibody activation (17,20,21). The only exception to this generality is
very short linkers which destabilize coil formation and very long linkers which insufficiently
restrict heterodimer location (data not shown).
To test MMP-dependent targeting in vivo, we have reformatted the coiled-coil fusion as
Fc conjugates based on the ds(Fv)-Fc format described in Chapter 4. In future mouse studies, we
will characterize the biodistribution of mmp-ds(shMFE)-Fc, scr-ds(shMFE)-Fc, and unmasked
ds(shMFE)-Fc in mice bearing a CEA-positive HT- 1 080-CEA tumor and a CEA-negative HT-
1080 tumor. The HT-1080 cell line was chosen due to its high levels of MMP-2
expression (9,22). Additionally, the mice will have a depot of CEA coated agarose beads in the
right shoulder to simulate antigen in healthy tissue (23).
Ideally, the mmp-ds(shMFE)-Fc construct should target the HT-1080-CEA tumor due to
the presence of both CEA and MMP-2, while having limited accumulation in the HT-1080 tumor
due to a lack of antigen and beads due to a lack of MMP-2. In contrast, unmasked ds(shMFE)-
Fc should target both the HT-1080-CEA tumor and antigen coated beads, and scr-ds(shMFE)-Fc
construct should have low labeling of all depots. It will also be interesting to assess the
microdistribution of these constructs within the tumors. The coiled-coil masking may allow the
antibodies to avoid the binding-site barrier and diffuse further into the tumor prior to being
uncloaked and binding antigen. Antibody distribution may ultimately depend on the distribution
of MMP-2 and the rate of linker cleavage.
131
5.5 - Works Cited
(1) Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer
therapeutics. Nat Rev Drug Discov. 2007;6:349-56.
(2) Nanney LB, Magid M, Stoscheck CM, King LE, Jr. Comparison of epidermal growth
factor binding and receptor distribution in normal human epidermis and epidermal
appendages. J Invest Dermatol. 1984;83:385-93.
(3) Welt S, Divgi CR, Real FX, et al. Quantitative analysis of antibody localization in human
metastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol.
1990;8:1894-906.
(4) Bronstein BR, Steele GD, Jr., Ensminger W, et al. The use and limitations of serial
plasma carcinoembryonic antigen (CEA) levels as a monitor of changing metastatic liver
tumor volume in patients receiving chemotherapy. Cancer. 1980;46:266-72.
(5) Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer.
2006;6:803-12.
(6) Hagan PL, Halpern SE, Chen A, et al. In vivo kinetics of radiolabeled monoclonal anti-
CEA antibodies in animal models. J Nucl Med. 1985;26:1418-23.
(7) Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer
progression. Nat Rev Cancer. 2002;2:161-74.
(8) Liu S, Wang H, Currie BM, et al. Matrix metalloproteinase-activated anthrax lethal toxin
demonstrates high potency in targeting tumor vasculature. J Biol Chem. 2008;283:529-
40.
(9) Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix
metalloproteinase inhibition. Nat Med. 2001;7:743-8.
(10) Albright CF, Graciani N, Han W, et al. Matrix metalloproteinase-activated doxorubicin
prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity. Mol
Cancer Ther. 2005;4:751-60.
(11) Harris TJ, von Maltzahn G, Derfus AM, Ruoslahti E, Bhatia SN. Proteolytic actuation of
nanoparticle self-assembly. Angew Chem Int Ed Engl. 2006;45:3161-5.
(12) Donaldson JM, Kari C, Fragoso RC, Rodeck U, Williams JC. Design and development of
masked therapeutic antibodies to limit off-target effects: Application to anti-EGFR
antibodies. Cancer Biol Ther. 2009;8.
(13) Thomas JM, Daugherty PS. Proligands with protease-regulated binding activity identified
from cell-displayed prodomain libraries. Protein Sci. 2009; 18:2053-9.
132
(14) Brinkmann U, Reiter Y, Jung SH, Lee B, Pastan I. A recombinant immunotoxin
containing a disulfide-stabilized Fv fragment. Proc Natl Acad Sci U S A. 1993;90:7538-
42.
(15) Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide
libraries. Nat Biotechnol. 1997;15:553-7.
(16) De Crescenzo G, Litowski JR, Hodges RS, O'Connor-McCourt MD. Real-time
monitoring of the interactions of two-stranded de novo designed coiled-coils: effect of
chain length on the kinetic and thermodynamic constants of binding. Biochemistry.
2003;42:1754-63.
(17) Turk BE, Huang LL, Piro ET, Cantley LC. Determination of protease cleavage site
motifs using mixture-based oriented peptide libraries. Nat Biotechnol. 2001;19:661-7.
(18) Arndt KM, Pelletier JN, Muller KM, Pluckthun A, Alber T. Comparison of in vivo
selection and rational design of heterodimeric coiled coils. Structure. 2002;10:1235-48.
(19) Schmidt MM, Thurber GM, Wittrup KD. Kinetics of anti-carcinoembryonic antigen
antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol
Immunother. 2008;57:1879-90.
(20) Potrich C, Tomazzolli R, Dalla Serra M, et al. Cytotoxic activity of a tumor protease-
activated pore-forming toxin. Bioconjug Chem. 2005;16:369-76.
(21) Abu Ajaj K, Graeser R, Fichtner I, Kratz F. In vitro and in vivo study of an albumin-
binding prodrug of doxorubicin that is cleaved by cathepsin B. Cancer Chemother
Pharmacol. 2009;64:413-8.
(22) Giambernardi TA, Grant GM, Taylor GP, et al. Overview of matrix metalloproteinase
expression in cultured human cells. Matrix Biol. 1998;16:483-96.
(23) Zuckier LS, Berkowitz EZ, Sattenberg RJ, Zhao QH, Deng HF, Scharff MD. Influence of
affinity and antigen density on antibody localization in a modifiable tumor targeting
model. Cancer Res. 2000;60:7008-13.
133
Appendix A - Amino acid sequences of selected clones
Chapter 2
A. 1 - shMFE scFv (yeast produced, non-disulfide stabilized)
EARPASQVKLEQSGAEVVKPGASVKLSCKASGFNIKDSYMHWLRQGPGQRLEWIGWID
PENGDTEYAPKFQGKATFTTDTSANTAYLGLSSLRPEDTAVYYCNEGTPTGPYYFDYW
GQGTLVTVSSGGGGSGGGGSGGGGSENVLTQSPSSMSASVGDRVTIACSASSSVPYMH
WFQQKPGKSPKLLIYSTSNLASGVPSRFSGSGSGTDYSLTISSVQPEDAATYYCQQRSSY
PLTFGGGTKLEIKAAAGSHHHHHH
A.2 - ds(shMFE) scFv (yeast produced, disulfide stabilized)
EARPASQVKLEQSGAEVVKPGASVKLSCKASGFNIKDSYMHWLRQGPGQCLEWIGWID
PENGDTEYAPKFQGKATFTTDTSANTAYLGLSSLRPEDTAVYYCNEGTPTGPYYFDYW
GQGTLVTVSSGGGGSGGGGSGGGGSENVLTQSPSSMSASVGDRVTIACSASSSVPYMH
WFQQKPGKSPKLLIYSTSNLASGVPSRFSGSGSGTDYSLTISSVQPEDAATYYCQQRSSY
PLTFGCGTKLEIKAAAGSHHHHHH
A.3 - sm3E scFv (yeast produced, non-disulfide stabilized)
EARPASQVKLEQSGAEVVKPGASVKLSCKASGFNIKDSYMHWLRQGPGQRLEWIGWID
PENGDTEYAPKFQGKATFTTDTSANTAYLGLSSLRPEDTAVYYCNEGTPTGPYYFDYW
GQGTLVTVSSGGGGSGGGGSGGGGSENVLTQSPSSMSVSVGDRVTIACSASSSVPYMH
WLQQKPGKSPKLLIYLTSNLASGVPSRFSGSGSGTDYSLTISSVQPEDAATYYCQQRSSY
PLTFGGGXKLEIKAAAGSHHHHHH
A.4 - ds(sm3E) scFv (yeast produced, disulfide stabilized)
EARPASQVKLEQSGAEVVKPGASVKLSCKASGFNIKDSYMHWLRQGPGQCLEWIGWID
PENGDTEYAPKFQGKATFTTDTSANTAYLGLSSLRPEDTAVYYCNEGTPTGPYYFDYW
GQGTLVTVSSGGGGSGGGGSGGGGSENVLTQSPSSMSVSVGDRVTIACSASSSVPYMH
WLQQKPGKSPKLLIYLTSNLASGVPSRFSGSGSGTDYSLTISSVQPEDAATYYCQQRSSY
PLTFGCGXKLEIKAAAGSHHHHHH
Chapter 4
The leader sequences of Hek secreted molecules are highlighted in italics and removed during
secretion.
The heavy chain variable domains for shMFE and sm3E are identical. This is denoted as
shMFE/sm3E below for constructs that were paired with both light chains
A.5 - shMFE/sm3E IgG heavy chain (Hek produced, co-secreted with clone A.6 or A.7)
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MGWSLILLFL VA VATTRQVKLEQSGAEVVKPGASVKLSCKASGFNIKDSYMHWLRQGPG
QRLEWIGWIDPENGDTEYAPKFQGKATFTTDTSANTAYLGLSSLRPEDTAVYYCNEGTP
TGPYYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE
PKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN
WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE
KTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
A.6 - shMFE IgG light chain (Hek produced, co-secreted with clone A.5)
MR VPAQLLGLLLLWLPGARCENVLTQSPSSMSASVGDRVTIACSASSSVPYMHWFQQKP
GKSPKLLIYSTSNLASGVPSRFSGSGSGTDYSLTISSVQPEDAATYYCQQRSSYPLTFGGG
TKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
A.7 - sm3E IgG light chain (Hek produced, co-secreted with clone A.5)
MR VPAQLLGLLLL WLPGARCENVLTQSPSSMSVSVGDRVTIACSASSSVPYMHWLQQKP
GKSPKLLIYLTSNLASGVPSRFSGSGSGTDYSLTISSVQPEDAATYYCQQRSSYPLTFGGG
TKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
A.8 - Hinge-Fc (Hek produced, co-secreted with several constructs)
MYRMQLLSCIALSLAL VTNSGGGASDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP
EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL
NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYP
SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
HNHYTQKSLSLSPGKGSDYKDDDDK
A.9 - ds(shMFE/sm3E)H-Fc (Hek produced, co-secreted with A.8/A.10 or A.8/A.11)
MGWSLILLFL VA VA TTRASGSGSQVKLEQSGAEVVKPGASVKLSCKASGFNIKDSYMHW
LRQGPGQCLEWIGWIDPENGDTEYAPKFQGKATFTTDTSANTAYLGLSSLRPEDTAVYY
CNEGTPTGPYYFDYWGQGTLVTVSSASDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI
SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV
KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
MHEALHNHYTQKSLSLSPGK
A.10 - ds(shMFE)L (Hek produced, co-secreted with A.8/A.9)
MR VPAQLLGLLLLWLPGARCASGSGSENVLTQSPSSMSASVGDRVTIACSASSSVPYMHW
FQQKPGKSPKLLIYSTSNLASGVPSRFSGSGSGTDYSLTISSVQPEDAATYYCQQRSSYPL
TFGCGTKLEIKAAAGSHHHHHH
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A. 11 - ds(sm3E)L (Hek produced, co-secreted with A.8/A.9)
MR VPAQLLGLLLLWLPGARCASGSGSENVLTQSPSSMSVSVGDRVTIACSASSSVPYMHW
LQQKPGKSPKLLIYLTSNLASGVPSRFSGSGSGTDYSLTISSVQPEDAATYYCQQRSSYPL
TFGCGTKLEIKAAAGSHHHHHH
Chapter 5
A. 12 - ds(sm3E)-FabL (Yeast surface displayed, co-secreted with A. 13)
LFASGSGSENVLTQSPSSMSVSVGDRVTIACSASSSVPYMHWLQQKPGKSPKLLIYLTSN
LASGVPSRFSGSGSGTDYSLTISSVQPEDAATYYCQQRSSYPLTFGCGTKLEIKATVAAPS
VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY
SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEGSHHHHHH
A.13 - ds(sm3E)-FabH-cAga2 (Yeast surface displayed, co-secreted with A.12)
EARPASQVKLEQSGAEVVKPGASVKLSCKASGFNIKDSYMHWLRQGPGQCLEWIGWID
PENGDTEYAPKFQGKATFTTDTSANTAYLGLSSLRPEDTAVYYCNEGTPTGPYYFDYW
GQGTLVTVSAGTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV
HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSNASEQKLI
SEEDLQELTTICEQIPSPTLESTPYSLSTTTILANGKAMQGVFEYYKSVTFVSNCGSHPSTT
SKGSPINTQ
A.14 - K3-6-ds(sm3E)-FabL (Yeast surface displayed, co-secreted with A. 15; X denotes 3-6
repeats of coiled-coil heptamer KVSALKE)
LFAS(KVSALKE)xGSGGGGSENVLTQSPSSMSVSVGDRVTIACSASSSVPYMHWLQQKP
GKSPKLLIYLTSNLASGVPSRFSGSGSGTDYSLTISSVQPEDAATYYCQQRSSYPLTFGCG
TKLEIKATVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEGSHHHH
HH
A.15 - E3-6-ds(sm3E)-FabH-cAga2 (Yeast surface displayed, co-secreted with A.14; X denotes 3-
6 repeats of coiled-coil heptamer EVSALEK)
EARPAS(EVSALEK)xGSGGGGSQVKLEQSGAEVVKPGASVKLSCKASGFNIKDSYMHW
LRQGPGQCLEWIGWIDPENGDTEYAPKFQGKATFTTDTSANTAYLGLSSLRPEDTAVYY
CNEGTPTGPYYFDYWGQGTLVTVSAGTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVD
KKVEPKSNASEQKLISEEDLQELTTICEQIPSPTLESTPYSLSTTTILANGKAMQGVFEYYK
SVTFVSNCGSHPSTTSKGSPINTQ
A. 16 - mmp-ds(shMFE/sm3E)H (Yeast produced, co-secreted with A. 17 or A. 18)
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EACGASTSVDELQAEVDQLEDENYALKTKVAQLRKKVEKLGSIPVSLRSGQVKLEQSG
AEVVKPGASVKLSCKASGFNIKDSYMHWLRQGPGQCLEWIGWIDPENGDTEYAPKFQG
KATFTTDTSANTAYLGLSSLRPEDTAVYYCNEGTPTGPYYFDYWGQGTLVTVSSDYKD
DDDK
A. 17 - mmp-ds(shMFE)L (Yeast produced, co-secreted with A. 16)
EACGASTTVAQLEEKVKTLRAENYELKSEVQRLEEQVAQLGSIPVSLRSGENVLTQSPSS
MSASVGDRVTIACSASSSVPYMHWFQQKPGKSPKLLIYSTSNLASGVPSRFSGSGSGTDY
SLTISSVQPEDAATYYCQQRSSYPLTFGCGTKLEIKAAAGSHHHHHH
A. 18 - mmp-ds(sm3E)L (Yeast produced, co-secreted with A. 16)
EACGASTTVAQLEEKVKTLRAENYELKSEVQRLEEQVAQLGSIPVSLRSGENVLTQSPSS
MSVSVGDRVTIACSASSSVPYMHWLQQKPGKSPKLLIYLTSNLASGVPSRFSGSGSGTD
YSLTISSVQPEDAATYYCQQRSSYPLTFGCGTKLEIKAAAGSHHHHHH
A.19 - scr-ds(shMFE/sm3E)H (Yeast produced, co-secreted with A.20 or A.21)
EACGASTSVDELQAEVDQLEDENYALKTKVAQLRKKVEKLGSIPLSRSVGQVKLEQSG
AEVVKPGASVKLSCKASGFNIKDSYMHWLRQGPGQCLEWIGWIDPENGDTEYAPKFQG
KATFTTDTSANTAYLGLSSLRPEDTAVYYCNEGTPTGPYYFDYWGQGTLVTVSSDYKD
DDDK
A.20 - scr-ds(shMFE)L (Yeast produced, co-secreted with A. 19)
EACGASTTVAQLEEKVKTLRAENYELKSEVQRLEEQVAQLGSIPLSRSVGENVLTQSPSS
MSASVGDRVTIACSASSSVPYMHWFQQKPGKSPKLLIYSTSNLASGVPSRFSGSGSGTDY
SLTISSVQPEDAATYYCQQRSSYPLTFGCGTKLEIKAAAGSHHHHHH
A.21 - scr-ds(sm3E)L (Yeast produced, co-secreted with A. 19)
EACGASTTVAQLEEKVKTLRAENYELKSEVQRLEEQVAQLGSIPLSRSVGENVLTQSPSS
MSVSVGDRVTIACSASSSVPYMHWLQQKPGKSPKLLIYLTSNLASGVPSRFSGSGSGTD
YSLTISSVQPEDAATYYCQQRSSYPLTFGCGTKLEIKAAAGSHHHHHH
A.22 - mmp-ds(A33)H (Yeast produced, co-secreted with A.23)
EACGASTSVDELQAEVDQLEDENYALKTKVAQLRKKVEKLGSIPVSLRSGEVQVMESG
GGLVKPGGSLRLSCAASGIGFSHYGISWVRQAPGKGLEWVAYIYPNYGSVDYASSVNG
RFTISLDNAQNSLYLQMNSLRAEDTAVYFCARDRGYYSGSRGTRLDLWGCGTLVTVSS
DYKDDDDK
A.23 - mmp-ds(A33)L (Yeast produced, co-secreted with A.22)
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EACGASTTVAQLEEKVKTLRAENYELKSEVQRLEEQVAQLGSIPVSLRSGELQMTQSPS
SLSASVGDRVTITCLASEFLFNGVSWYQQKPGKCPKFLIYGASNLESGVPSRFSGSGSGT
DFTLTISSLQPEDVATYYCLGGYSGSSGLTFGGGTKVEIKRAAGSHHHHHH
A.24 - mmp-ds(806)H (Yeast produced, co-secreted with A.25)
EACGASTSVDELQAEVDQLEDENYALKTKVAQLRKKVEKLGSIPVSLRSGQLQESGPSL
VKPSQSLSLTCTVTGYSITSDFAWNWIRQFPGNKLEWMGYISYSGNTRYNPSLKSRISITR
DTSKNQFFLQLNSVTIEDTATYYCVTAGRGFPYWGCGTLVTVSSDYKDDDDK
A.25 - mmp-ds(806)L (Yeast produced, co-secreted with A.24)
EACGASTTVAQLEEKVKTLRAENYELKSEVQRLEEQVAQLGSIPVSLRSGDILMTQSPSS
MSVSLGDTVSITCHSSQDINSNIGWLQQRPGKCFKGLIYHGTNLDDEVPSRFSGSGSGAD
YSLTISSLESEDFADYYCVQYAQFPWTFGGGTKLEIKRAAGSHHHHHH
A.26 - mmp-ds(shMFE)H-Fc (Hek produced, co-secreted with A.8/A.27)
MYRMQLLSCIALSLAL VTNSGGGCGASTSVDELQAEVDQLEDENYALKTKVAQLRKKVE
KLGSIPVSLRSGQVKLEQSGAEVVKPGASVKLSCKASGFNIKDSYMHWLRQGPGQCLE
WIGWIDPENGDTEYAPKFQGKATFTTDTSANTAYLGLSSLRPEDTAVYYCNEGTPTGPY
YFDYWGQGTLVTVSSASDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV
VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAV
EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
QKSLSLSPGK
A.27 - mmp-ds(shMFE)L (Hek produced, co-secreted with A.8/A.26)
MYRMQLLSCIALSLAL VTNSGGGCGASTTVAQLEEKVKTLRAENYELKSEVQRLEEQVAQ
LGSIPVSLRSGENVLTQSPSSMSASVGDRVTIACSASSSVPYMHWFQQKPGKSPKLLIYST
SNLASGVPSRFSGSGSGTDYSLTISSVQPEDAATYYCQQRSSYPLTFGCGTKLEIKAAAG
SHHHHHH
A.28 - scr-ds(shMFE)H-Fc (Hek produced, co-secreted with A.8/A.29)
MYRMQLLSCIALSLAL VTNSGGGCGASTSVDELQAEVDQLEDENYALKTKVAQLRKKVE
KLGSIPLSRSVGQVKLEQSGAEVVKPGASVKLSCKASGFNIKDSYMHWLRQGPGQCLE
WIGWIDPENGDTEYAPKFQGKATFTTDTSANTAYLGLSSLRPEDTAVYYCNEGTPTGPY
YFDYWGQGTLVTVSSASDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV
VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAV
EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
QKSLSLSPGK
A.29 - scr-ds(shMFE)L (Hek produced, co-secreted with A.8/A.28)
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MYRMQLLSCIALSLALVTNSGGGCGASTTVAQLEEKVKTLRAENYELKSEVQRLEEQVAQ
LGSIPLSRSVGENVLTQSPSSMSASVGDRVTIACSASSSVPYMHWFQQKPGKSPKLLIYST
SNLASGVPSRFSGSGSGTDYSLTISSVQPEDAATYYCQQRSSYPLTFGCGTKLEIKAAAG
SHHHHHH
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Appendix B - Size-dependent parameter data sets
B. 1 - Effective diffusivity (D) data
MW Diffusivity
Name (kDa) Radius (nm) (cm2/s) Tumor line Reference
Na-FITC 0.376 0.45 6.40E-06 VX2 carcinoma (1)
Na-FITC 0.376 0.45 4.30E-06 U87/Mu89 (2)
Na-FITC Average 0.376 0.45 5.35E-06
Dextran 20 3.2 7.50E-07 VX2 (1)
Dextran 40 5.0 4.20E-07 VX2 (1)
Dextran 70 6.5 1.90E-07 VX2 (1)
Dextran 2000 22.1 2.47E-08 U87/Mu89 (2)
Dextran 2000 22.1 4.11E-09 U87/Mu89 (2)
Dextran 2000
Average 2000 19.2 1.44E-08
Lactalbumin 21.5 2.54 1.01E-06 U87/Mu89 (2)
Fab 50 3.36 2.70E-07 LS174T (3)
IgG 150 4.85 1.30E-07 LS174T (3)
IgG 150 4.85 9.6E-09 HSTS 26T (4)
lgG 150 4.85 1.9E-07 LS174T (4)
IgG 150 4.85 1.9E-07 MCaIV (4)
IgG 150 4.85 8.7E-08 U87 (4)
IgG 150 4.85 1.91E-07 U87/Mu89 (2)
IgG 150 4.85 9.38E-08 U87/Mu89 (2)
IgG Average 150 4.85 1.27E-07
lgM 900 8.81 7.7E-08 LS174T (5)
IgM 900 8.81 1.05E-07 U87/Mu89 (2)
IgM 900 8.81 4.30E-08 U87/Mu89 (2)
IgM Average 900 8.81 7.5E-08
Liposome 76.2 2.97E-09 U87/Mu89 (2)
Table B.1 - Effective diffusivity (D) for molecules of various sizes. Data points were collected
from experimental studies reported in the literature. Experiments were primarily performed in
mouse xenograft models in vivo and include studies on small molecule tracers, proteins, and
dextrans. All molecules are non-specific meaning they have no affinity for the tumor tissue.
Bovine serum albumin (BSA) diffusivities reported in the literature were excluded from the data
set as the negatively charged nature of these molecules can significantly influence their
interstitial transport. For molecules characterized in multiple tumor types, an average value was
determined and used in the fit. When not directly stated in the reference, molecular radii for
globular proteins were estimated as R = 0.912*MW 333 . This relationship was derived from
fitting data in supplemental reference (6). Molecular radii for Dextran 40, 70, and 2000 are the
average of values given in references (1) and (7). Data values reported in graphical form were
estimated using the DataThief program (http://www.datathief.org/).
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B.2 - Tumor void fraction (s) data
MW Available volume
Name (kDa) Radius fraction Tumor Reference
Dextran 10 2.7 0.26 Rat fibrosarcoma (8)
Dextran 20 3.2 0.28 Rat fibrosarcoma (8)
Dextran 40 5.0 0.28 Rat fibrosarcoma (8)
Dextran 70 6.5 0.1 Rat fibrosarcoma (8)
Dextran 2000 22.1 0.055 Rat fibrosarcoma (8)
Cationized albumin 66 3.69 0.29 Rat mammary tumor (9)
IgG 150 4.85 0.24 Rat mammary tumor (9)
Table B.2 - Available volume fraction in the tumor (s) for molecules of various sizes. Data
points were collected from experimental studies reported in the literature. All experiments were
performed in rat tumor tissues either ex vivo (8) or in vivo (9). All molecules are non-specific
meaning they have no significant affinity for the tumor tissue. Void fraction data for native
bovine serum albumin (BSA) were excluded from the analysis as the surface charge of these
molecules impacts their tumor distribution (9). Instead, cationized albumin with a pI of 7.6 was
used as a tracer. Data points in reference (9) were converted from relative volume fractions to
absolute values by dividing by the interstitial volume Vi estimated as 0.5. When not directly
stated in the reference, molecular radii for globular proteins were estimated as R =
0.912*MW. 333 . Molecular radii for Dextran 40, 70, and 2000 are the average of values given in
references (1) and (7). Data values reported in graphical form were estimated using the
DataThief program (http://www.datathief.org/).
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B.3 - Capillary permeability (P) data
MW Permeability
Name (kDa) Radius (nm) (10-7 cm/s) Tumor type Reference
Dextran 3.3 1.5 154 LS174T (7)
Dextran 10 2.7 32 LS174T (7)
Dextran 40 5.0 9.5 LS174T (7)
Dextran 70 6.5 9.8 LS174T (7)
Dextran 2000 22.1 1.7 LS174T (7)
Mouse Fc fragment 25 2.66 3.74 LS174T (6)
Mouse Fab fragment 25 2.66 4.61 LS174T (6)
Ovalbumin 45 3.24 5.77 LS174T (6)
Concanavalin A 104 4.28 1.53 LS174T (6)
Mouse F(ab')2fragment 110 4.36 1.51 LS174T (6)
Mouse IgG 160 4.94 2.82 LS174T (6)
Liposome 45.0 0.2 LS174T (6)
Liposome 60.0 0.155 LS174T (10)
Table B.3 - Effective capillary permeability (P) for molecules of various sizes. Data points were
collected from experimental studies reported in the literature. Experiments were performed in
mouse xenograft models in vivo by quantifying the extravasation of fluorescent tracers into the
tumor. Since extravasation may contain both convective and diffusive components, these are
apparent permeability values. All molecules are non-specific meaning they have no affinity for
the tumor tissue. The higher apparent permeability values for dextran molecules (7) compared
to proteins (6) may be due to geometry effects (linear vs. globular molecules), charge effects, or
differences in the experimental assays. Bovine serum albumin (BSA) permeabilities reported in
the literature were excluded from the data set as the negative surface charge on these molecules
can retard transcapillary flux (11). Molecular radii for Dextran 40, 70, and 2000 are the average
of values given in references (1) and (7). Data values reported in graphical form were
estimated using the DataThief program (http://www.datathief.org/).
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B.4 - Plasma clearance (kciear) data
A B AUC
Eff. MW Rad. (%ID (%ID ka kb (%ID*hr kolegr
Format (kDa) (nm) /mL) /mL) (hr~') (hr1 ) /mL) (hr ) Ref.
0.50 0.73 6.79 0.07 1.36 0.03 7.01 7.13 (12)
0.62 0.78 6.91 0.68 1.01 0.13 12.07 4.14 (12)
0.99 0.91 8.59 0.09 1.37 0.03 8.97 5.58 (12)
1.19 0.97 5.27 0.16 1.25 0.02 12.91 3.87 (12)
7 1.74 49.86 0.08 2.83 0.03 20.19 2.48 (13,14)
DTPA
DOTA-
Benzene
DOTA-FITC
DOTA2-Tyr-
Lys
Affibody
Affibody
dimer
scFv
scFv
scFv
scFv dimer
scFv dimer
scFv dimer
scFv dimer
Minibody
Minibody
Minibody
F(ab') 2
F(ab')2
scFv-PEG
Tetramer
TFM
scFv dimer-
PEG
2.28
2.74
2.74
2.74
3.47
3.47
3.47
3.47
3.93
3.93
3.93
49.18
47.00
14.40
49.10
49.10
48.15
43.85
33.00
22.92
26.44
18.80
0.80
3.03
3.77
0.54
0.80
0.76
3.04
6.42
8.31
7.57
30.00
3.10
3.20
4.70
10.40
2.81
1.17
0.75
2.76
0.66
0.48
1.05
0.12
0.11
0.21
0.04
0.05
0.05
0.05
0.24
0.07
0.06
0.13
22.82
42.23
21.02
17.52
33.47
57.49
124.43
38.71
157.83
189.75
248.67
4.37 12.73 26.39 1.41 0.11 248.94
4.37 49.60 0.40 0.49 0.01 135.77
4.62 37.50 12.54 0.95 0.05 300.93
4.62 40.60 6.58 0.98 0.07 137.92
4.85 42.70 7.29 0.34 0.06 255.56
2.19
1.18
2.38
2.85
1.49
0.87
0.40
1.29
0.32
0.26
0.20
0.20
0.37
0.17
0.36
0.20
(13,15)
(16)
(17)
(18,19)
(18)
(20)
(21)
(17)
(22)
(22,23)
(17)
(17)
(24)
(19)
(18)
(24)
300 6.11 34.07 16.00 1.15 0.03 669.63 0.07 (19)
150 4.85 30.50
150 4.85 15.42
150 4.85 33.42
19.50
22.90
16.58
0.53 0.01 2590.01
0.19 0.01 2281.96
0.43 0.01 2413.93
0.02 (25,26)
0.02 (17)
0.02 (27)
45 14.20 35.80 0.39 0.02 1533.96 0.03 (28)
50.00 0.03 1443.72 0.03 (29)
40 43.60 30.60 0.05 0.05 1514.29 0.03 (30)
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15.6
27
27
33
55
55
55
55
80
80
80
110
110
130
130
150
IgG
IgG
IgG
PEG-
liposome
PEG-
liposome
PEG-
liposome
AUC
MW (%lD*hr/m kolegr
Format (kDa) Radius L) (hr ) Ref.
PEG 6.00 1.41 6.17 8.10 (31)
PEG 20.00 3.08 110.30 0.45 (31)
PEG 50.00 5.59 600.00 0.08 (31)
PEG 170.00 12.39 1106.70 0.05 (31)
Table B.4 - Plasma clearance rates for molecules of various sizes. Experimental measurements
of plasma concentration over time following a bolus iv administration were collected from the
literature for proteins, PEG chains, and liposomes of various sizes. Data points were pooled
prior to fitting for identical molecules or closely related affinity variants measured in multiple
references. Data points were fit to a bi-exponential clearance model of the form:
[Ab] plasma (t) = Ae-kat + Be-kbt
where [Ab]piasma(t) is the macromolecule's plasma concentration in %ID/mL, A and B are the
fraction of alpha and beta clearance in %ID/mL, and ka and kb are the clearance rates for the
alpha and beta phases with units h-1. Fitting was performed in MATLAB using the least squares
method. For data sets with no t = 0 time point, a plasma concentration of 50 %ID/mL was used
for the initial concentration based on the assumption of a 2 mL plasma volume in mice. The
plasma area under the curve in units %ID*hr/mL was calculated for each data set as:
AUC = +-
ka kb
The single exponential plasma clearance term can be calculated as:
kclear = IC AUCI
A[Ab]o)
where [Ab]o is the initial plasma concentration of the targeting agent estimated as 50 %ID/mL
(again assuming a 2 mL mouse plasma volume). When not directly stated in the reference,
molecular radii were estimated as R = 0.912*MWo333 for globular proteins and R = 0.44*MW 6 s
for PEG chains. The PEG relationship was fit from data in supplemental reference (32).
144
B.5 - Max tumor uptake data
Eff. Peak tumor
MW Radius conc.
Format Clone (kDa) (nm) Label Tumor type (%ID/g) Ref.
Affibody ZHer2:342 7 1.74 99Tc SKOV-3 9.1 (33)
Affibody ZHer2:342 7 1.74 99Tc SKOV-3 7.0 (34)
Affibody ZHer2:342 7 1.74 99Tc SKOV-3 11.5 (35)
Affibody ZHer2:342 7 1.74 1In SKOV-3 14.0 (14)
Affibody dimer (ZHer2:4)2  15.6 2.28 99Tc SKOV-3 2.6 (15)
scFv 4D5 29 2.74 99Tc SKOV-3 1.6 (18)
scFv 4D5 29 2.74 99Tc SKOV-3 1.8 (19)
scFv-barstar 4D5 40 3.12 99Tc SKOV-3 1.0 (36)
scFv dimer 4D5 66 3.69 **Tc SKOV-3 1.6 (18)
scFv dimer 4D5 66 3.69 99Tc SKOV-3 2.1 (19)
Minibody 10H8 80 3.93 111in MCF-7/Her2 5.7 (22)
Minibody 4D5v8 80 3.93 "Cu MCF-7/Her2 4.3 (22)
scFv-barstar
dimer 4D5 81 3.95 99Tc SKOV-3 3.4 (36)
scFv-Fc DM 4D5v8 105 4.30 "Cu MCF-7/Her2 12.2 (22)
scFv tetramer 4D5 130 4.62 99Tc SKOV-3 4.3 (18)
scFv tetramer 4D5 130 4.62 **Tc SKOV-3 2.8 (19)
scFv-barstar
trimer 4D5 132 4.64 99Tc SKOV-3 7.0 (36)
scFv-PEG 4D5 133 4.66 99Tc SKOV-3 9.3 (19)
scFv dimer-PEG 4D5 309 6.17 99Tc SKOV-3 14.9 (19)
IgG 4D5 150 4.85 1In MCF-7/Her2 32.5 (25)
IgG 4D5 150 4.85 m1n MCF-7/Her2 33.9 (22)
IgG 10H8 150 4.85 1In MCF-7/Her2 39.8 (22)
Table B.5 - Peak tumor concentrations for HER2 targeting molecules of various sizes. Data
points were collected from mouse biodistribution studies reported in the literature. All studies
report the uptake of HER2 binding molecules in HER2 expressing tumor xenografts. For each
biodistribution time course, the highest reported concentration of targeting agent in the tumor
was included in the data set. Tumor uptake measurements with only a single time point were
excluded. Additionally, only data sets using residualizing radiometal labels (99Tc, m'In, and
64Cu) were included. The slow clearance of these labels from the tumor helps maintain tumor
concentrations close to the peak level for longer periods of time and reduces errors due to
infrequent sampling. For cases in which multiple affinity variants of a single molecule were
tested, only the uptake for the highest affinity molecule was included. When not directly stated
in the reference, molecular radii for globular proteins were estimated as R = 0.912*MWO.3 33 .
Data values reported in graphical form were estimated using the DataThief program
(http://www.datathief.org/).
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Appendix C - Site-specific PEGylation of anti-CEA ds(scFv) molecules
Introduction
Conjugation to polymer chains such as polyethylene glycol (PEG) is a well-characterized
method for increasing protein molecular weight. The random conformation of PEG chains and
their ability to coordinate water molecules produces a large effective hydrodynamic radius.
PEGylation has been shown to reduce renal filtration and increase serum persistence, as well as
protect proteins from protease cleavage and immunogenicity (37). As described in Chapter 3,
reducing serum clearance can increase tumor uptake, particularly for small targeting agents such
as antibody fragments and peptides (38-40).
NHS-activated PEG chains can be conjugated to proteins through random reaction with
primary amines on surface lysines. The products are typically heterogeneous, however, and may
exhibit reduced activity if PEG chains react near the antibody active site (39). Alternatively,
PEG molecules can be site-specifically reacted with a free cysteine residue on the protein,
including cysteines native to the molecule or inserted through mutagenesis (41-43). By
inserting the cysteine residue distal to the antibody active site, binding activity is typically less
significantly impacted (43,44). Here we describe a method for site-specifically reacting
maleimide-PEG molecules to a c-terminal cysteine in a disulfide stabilized scFv. We also
describe how these PEGylated antibody fragments can be used to make monovalent quantum dot
conjugates for imaging single receptors on cells.
Methods
Protein production
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Plasmids encoding disulfide stabilized variants of the anti-CEA scFvs shMFE and sm3E
plasmids were constructed as described in Chapter 2. QuikChange mutagenesis was performed
to insert a free cysteine at the c-terminus of the ds(scFv)s directly preceding the His tag to
produce ds(shMFE)-cys and ds(sm3E)-cys. Mutations were confirmed by sequencing. Plasmids
were transformed into the YVH10 strain of yeast using the EZ Yeast Kit (Zymo Research) and
plated on SD-CAA media supplemented with 40 pg/mL tryptophan. Individual colonies were
grown in 1 L flasks and secretion induced for 48 hours at 37*C as described previously (45).
The cleared supernatant was concentrated using a 10 kDa ultrafiltration membrane (Millipore)
and the His-tagged protein purified with Talon metal affinity resin (BD Biosciences) following
the manufacturer's batch-column protocol. Monovalent scFvs were further purified by size
exclusion chromatography on a Superdex 75 column (GE Healthcare) and eluted into
PEGylation buffer (100 mM Na2HPO4, 500 mM NaCl, 2 mM EDTA, pH 6.5).
Site-specific PEGylation
ds(shMFE)-cys or ds(sm3E)-cys at a concentration of 0.5 - 1 mg/mL was co-incubated with a 5
fold molar excess of 5 kDa or 20 kDa PEG-maleimide (Nektar) and immobilized TCEP reducing
gel (Pierce) at a concentration of 150 iL gel per 1 mL reaction (Figure C.1A). Using TCEP
resin instead of soluble TCEP or DTT to reduce the c-terminal cysteine prevented reduction of
the partially buried disulfide bonds in the protein. The reaction mixture was incubated at 25*C
for 5 hours on a rocker. The TCEP resin was then removed by centrifugation and the unreacted
PEG by ion exchange chromatography on a Hi-Q column (GE Healthcare) equilibrated with 20
mM Tris, pH 8.2. PEGylated scFvs were separated from unconjugated scFvs on a Superdex 75
column at a flow rate of 0.5 mL/min and eluted in PBS. The PEGylation efficiency and
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conjugate purity were assessed by SDS-PAGE electrophoresis on a 12% Bis-Tris gel
(Invitrogen). Binding activity of the 20 kDa PEGylated molecules was tested by Kj titrations on
fixed LS174T cells as described previously (46).
Monovalent conjugation to quantum dots
As part of a collaboration with Dr. Mark Howarth and Professor Alice Ting to make monovalent
antibody conjugated small quantum dots (sQDs), the 5 kDa PEGylated ds(sm3E) molecules were
incubated at varying concentrations with the sQDs for 1 hour in PBS (47). The conjugates were
then separated on a 1% agarose gel, visualized under UV light, and the single antibody-sQD
band excised and purified. Cell labeling of the conjugates was tested on CHO A7 cells co-
transfected with CEA and Blue Fluorescent Protein (BFP). Cells were incubated for 10 minutes
at 40C with 20 nM sQD-ds(sm3E)-PEG5 and imaged live. CHO A7 cells transfected with AP-
LDL instead of CEA were used as a negative control, as well as non-conjugated sQD molecules
Results and Discussion
Protein production and PEGylation
The ds(shMFE)-cys and ds(sm3E)-cys proteins were secreted in yeast at similar levels as the
non-cysteine containing variants ds(shMFE) and ds(sm3E) with final purified yields on the order
of 1 mg/L. The molecules secreted as a mix of disulfide stabilized monomers, dimers, trimers,
and higher order aggregates, which could be separated by size exclusion chromatography to
isolate the monomeric species. The purified monomers did not react directly with maleimide-
PEG, suggesting that the C-terminal cysteine was not reactive and likely in a mixed disulfide
with glutathione or some other small molecule. Attempts to reduce the C-terminal cysteine with
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soluble DTT or TCEP prior to PEGylation led to the formation of multiple high MW PEG-scFv
bands suggesting that the interdomain disulfide bonds were being reduced and reacting with the
PEG (data not shown). In contrast, reduction with immobilized TCEP reducing gel (Pierce)
during conjugation led to the formation of a single dominant PEG-scFv band at the appropriate
size. Presumably, the large size of the agarose resin sterically precludes the TCEP molecules
from reaching the internal disulfide bond while maintaining access to the exposed C-terminal
cysteine residue. Additionally, since TCEP, unlike DTT, is poorly reactive with maleimide, the
reduction and conjugation steps could be carried out simultaneously. The final conjugation
efficiency was 60-80% and the desired PEG-scFv molecule could be purified to >95% purity by
ion exchange and size exclusion chromatography (Figure C. 1 B).
A B 12
TCEP resin Maleimide-PEG
V V VH vL v v
S-S"( H
Figure C.l - Site-specific PEGylation reaction. A: Schematic of the reaction conditions.
Immobilized TCEP resin was used to specifically reduce the C-terminal cysteine residue which
was then conjugated with maleimide activated PEG. The X denotes an unknown species,
presumably glutathione, that forms a mixed disulfide with the cysteine during secretion. B:
Coomassie stained Bis-Tris gel showing ds(sm3E)-PEG20 in lane 1 and non-PEGylated ds(sm3E)
in lane 2.
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Quantum dot conjugation
In a collaborative project with Dr. Mark Howarth and Professor Alice Ting at MIT to create
single molecule imaging reagents, 5 kDa PEGylated sm3E variants were conjugated to small
quantum dot (sQDs). The conjugation reaction creates a heterogeneous product with varying
numbers of antibody fragments per sQD molecules (Figure C.2A). The different species could
be resolved and the desired monovalent conjugate purified by 1% agarose gel electrophoresis
(Figure C.2B). In contrast, sQD reaction with a non-PEGylated ds(sm3E) molecule produced
heterogeneous conjugates that were not sufficiently different in size to be resolved and purified
on the gel (data not shown). The ds(sm3E)-PEG5-sQD conjugates retain their binding activity to
CEA as demonstrated in live cell imaging studies (Figure C.2C).
A Ratio Ab:QD0 012 023 047 094 19 38 75 15
sQD-Ab2-+
sQD-Ab,-+
sQD-+ an e
B C QOD BFP DIC
Bulk Purified sOD-Ab,
CEA
sQD-Ab2-
D-Ab+ sOD-AbsQD- AP-LDLR
sQD-D
CEA M
150
Figure C.2 - Production and characterization of ds(sm3E)-PEG 5-sQD conjugates. A: 1%
agarose gel showing conjugates formed at a variety of antibody-sQD ratios. As expected, an
increase in the relative concentration of antibodies produces molecules with several antibodies
per sQD. B: The desired single antibody species can be resolved and excised from a 1% agarose
gel. C: The ds(sm3E)-PEG 5-sQD conjugate labels CEA expressing CHO cells. Control
experiments using non-CEA expressing cells (AP-LDLR) or non antibody conjugated sQD
molecules produce no labeling.
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